10 Annual MidAmerica Healthcare Venture Forum (Conference Workbook)

V E N T U R E

F O R U M

D e c e m b e r 4 , 2 0 1 2 • H y a t t M i n n e a p o l i s, M N

Jointly Presented By: ®

W W W. M I D A M E R I C A H E A L T H C A R E F O R U M . C O M

Financial Audit Tax Compliance Tax/Legal Structure State and Local Tax Research Credit Services Information Risk Management IPO Readiness Services Mergers and Acquisitions International Services

Helping you navigate the challenges from idea to leadership Andrew Lanik

Kevin Smith

Andy is an audit partner in the Minneapolis office of KPMG. Andy has over 14 years of healthcare and not-for-profit audit experience. He serves various healthcare organizations including physician organizations, critical access hospitals, specialty hospitals, academic tertiary referral centers, and healthcare organizations.

Kevin is a tax partner who leads the Venture Capital, Middle Market, and Life Science tax practices in Minneapolis. He has experience serving the tax needs of venture capital and private equity firms and the various medical device, pharmaceutical, cleantech, and high-technology companies in which they invest.

Andrew Lanik 612-305-5405 alanik@kpmg.com

Kevin Smith 612-305-5908 ksmith@kpmg.com

Brian Mensink

Overview

KPMG LLP has maintained a continuous commitment to providing leadership, integrity, and quality service to the Twin Cities' markets since 1904.

We offer clients, emerging to FORTUNE 500 companies, the scale, global reach, industry insights, and multidisciplinary range of services they demand.

How we can help

Dawn Courrier

Brian is an audit partner who serves life science, cleantech and agri-business clients in Minneapolis.

His experience includes SEC filings, carve-out financial statements, pension plans, acquisitions and divestitures, international issues, financial reporting, private and public offerings, restructurings, Sarbanes-Oxley 404, and technical accounting matters.

Dawn is the partner in charge of the Minneapolis Tax practice. She has experience serving a broad range of multinational and multistate companies, from FORTUNE 500 public companies to start-up entities. Her current and past clients include leaders in the medical technology industries, retail, consumer markets, and manufacturing.

Brian Mensink 612-305-5855 bmensink@kpmg.com

Dawn Courrier 612-305-5453 dcourrier@kpmg.com

Our services help to address the interrelated set of needs that companies have on their journey to leadership. Each of our services draws upon the knowledge, experience, and networks of KPMG and brings them to the start-up and early-stage companies in a timely and cost-effective manner.

KPMG LLP 4200 Wells Fargo Center 90 South 7th Street Minneapolis, MN 55402 612-305-5000

© 2012 KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. Printed in the U.S.A. The KPMG name, logo and “cutting through complexity” are registered trademarks or trademarks of KPMG International. NDPPS 127266

kpmg.com

Helping you help others.

Lindquist & Vennum attorneys work alongside more than 30 medical device and life sciences companies, from early stage ventures to Fortune 500 companies. Our reputation with private equity funds, venture capital firms, and investment banks helps create lasting financial relationships for our emerging company clients.

Visit lindquist.com/lifesciences to learn more.

▪ Venture finance

▪ Technology licensing

▪ Private and public offerings

▪ Regulatory compliance

▪ Strategic alliances

▪ Intellectual property

▪ Mergers and acquisitions

▪ Manufacturing and distribution

Jointly Presented By: ®

V E N T U R E

F O R U M

D e c e m b e r 4 , 2 0 1 2 • H y a t t M i n n e a p o l i s, M N

December 4, 2012 Dear Conference Participant: Welcome to the 10th Annual MidAmerica Healthcare Venture Forum presented by The Mid-America Healthcare Investors Network (MHIN), IBF In¬ternational Business Forum, and, this year, hosted by LifeScience Alley.

We are thrilled to be back in Minnesota, the epicenter of health innovation and home to a number of prestigious names including Medtronic, St. Jude, 3M, United Health Group, Mayo Clinic, Cargill and the University of Minnesota.

Over the course of the day, industry experts will share their perspectives on the current market and strategies on how to succeed in our uncertain times. This year’s agenda will address such topics as: • • • • • • • • •

Industry Update: State of life science venture investing and Impact of the 2012 elections Keynote Presentation from Dr. Eric Kaler, President of the University of Minnesota Mobile Technology Disrupting the Traditional Healthcare Business Models Views From Serial Entrepreneurs: The Landscape Today vs. 5-10 Years Ago Healthcare Investment Trend: Shift from Medical to Industrial Economic Value Analysis: Innovation and How We Pay For It Investing in Agri-Health: Opportunities in the Midwest New Models of Financing in Biopharmaceutical Product Development Plus: Investment Presentations from 30 Midwest startup companies

We are delighted that so many of you are able to join us for the 10th anniversary of this forum. We look forward to learning from the various industry panels, reviewing the variety of excellent investment opportunities and the opportunity to develop new business relationships that enable additional success!!

Sincerely,

Peter Kleinhenz

Kathleen A. Tune

Dale Wahlstrom Venture Partner, Fletcher Spaght Partner President & CEO Managing Director, CID Thomas, McNerney & Partners LifeScience Alley and Conference Founder & Chairman Conference Co-Chair & President of MHIN The BioBusiness Alliance of Minnesota Host Committee Chair

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM

AGENDA

7:00 – 7:40 am

Continental Breakfast and Conference Registration

7:40 – 7:50 am

Welcome and Opening Remarks

Conference Chairman: Peter Kleinhenz Venture Partner – Fletcher Spaght Managing Director – CID

7:50 – 8:10 am

Industry Update • State of life science venture investing • Impact of the 2012 elections

Mark Heesen President

National Venture Capital Association (NVCA)

AG EN DA

8:10 – 8:30 am

Advancing Commercialization at the University of Minnesota • Transformation as a technology transfer hub • A national leader in simplifying the movement of intellectual property onto the marketplace • Ongoing innovative research at Minnesota’s only comprehensive research university

Guest Speaker:

Eric W. Kaler, Ph.D. President University of Minnesota 8:30 – 9:15 am

Mobile Technology Disrupting the Traditional Healthcare Business Models

Panelists:

Brian Bischoff

CEO HealthSense

David Van Sickle

CEO Asthmapolis

James Burgum

Co-Founder Arthur Ventures

John West

Founder & Chairman The Whistle

Moderator:

Chris Hoffmann

Senior Director & Chief Marketing Officer TripleTree

9:15 – 10:00 am

Views From Serial Entrepreneurs: The Landscape Today vs. 5-10 Years Ago

Panelists: Michael Dale President & CEO

Medical Device Innovations, Inc. Stan Rose, Ph.D. Chief Commercial Officer Nabsys Mark Gehring Co-Founder & President Asthmapolis Moderator: Barbara Lano Rummel Partner Lindquist & Vennum, LLP 10:00 – 10:30 am

Networking and Refreshment Break

10:30 – 11:15 am

Healthcare Investment Trend: Shift from Medical to Industrial

AG EN DA

Panelists: John Banta CEO & Managing Director IllinoisVENTURES J. Thomas Halverson, Jr. Managing Director and Group Head Clean Technology & Industrials Piper Jaffray & Co. Greg Young Managing Director Burrill & Company Moderator: William Faulkner CEO Ascenix Biotech 11:15 – 12:30 pm

11:20 – 11:30 am 11:30 – 11:40 am 11:40 – 11:50 am 11:50 – 12:00 pm 12:00 – 12:10 pm 12:10 – 12:20 pm 12:20 – 12:30 pm

Company Showcase Medical Devices

Biopharmaceuticals/ Regenerative Medicine

Diagnostics/Tools

CardioInsight Technologies, Inc.

Shamrock Structures

Ativa Medical

Advanced Circulatory Systems, Inc. AllTranz, Inc.

IntelliCyt Corporation

Monteris Medical Corp.

Altheus Therapeutics, Inc.

Siloam Biosciences, Inc.

ALung Technologies, Inc.

Respira Therapeutics, Inc.

Intuitive Biosciences

Flow Forward Medical, LLC

FluGen, Inc.

Securus Medical Group, Inc.

Metactive Medical, LLC

Cell Habitats, Inc.

Delphinus Medical Technologies

Imricor Medical Systems

SironRX Therapeutics, Inc.

12:30 – 1:20 pm

Luncheon Reception

1:20 – 2:30 pm

Company Showcase

1:35 – 1:45 pm 1:45 – 1:55 pm 1:55 – 2:05 pm 2:05 – 2:15 pm 2:15 – 2:25 pm

2:30 – 3:15 pm

Medical Devices

HealthIT/Mobile Health

NxThera, Inc.

Healthsense

Preceptis Medical, Inc.

Zipnosis

Pulse Therapeutics, Inc.

Abiogenix

Diagnostic Photonics

QuickCheck Health

HistoSonics, Inc.

Ubiqi Health, Inc.

Economic Value Analysis: Innovation and How We Pay For It

AG EN DA

Panelists:

Robert Plourde

Vice President, Innovation and R&D UnitedHealth Group Dr. Jeremy Friese

Founder and CEO, Evidentia Health

Medical Director for New Ventures and Business Development in the Center for

Individualized Medicine and Associate Chair of Finance in the Department of Radiology, Mayo Clinic Julie Brewer

Vice President, CVG Strategies Medtronic

Moderator:

David Cassak

Vice President, Content, Managing Director, Medical Devices Elsevier Business Intelligence 3:15 – 3:45 pm

Networking and Refreshment Break

3:45 – 4:30 pm

Investing in Agri-Health: Opportunities in the Midwest

Panelists:

Diana Twyman

Business Development Executive Integrated Project Management Dave Wagner

Vice President, External Partner Development General Mills, Inc. Moderator:

Dan Broderick

President GAIN

4:30 – 5:15 pm

New Models of Financing in Biopharmaceutical Product Development

Panelists:

Baiju Shah Chief Executive Officer BioMotiv

Steven Kuemmerle Head, Venture Investments

Abbott Biotech Ventures Inc. Julia Owens

Founder & Chief Executive Officer Atterocor, Inc.

5:15 – 5:25 pm

Closing Remarks

5:25 – 7:00 pm

Minnesota Warm-up Reception (Joint reception with LSA 2012 Conference)

7:00 pm

Conference Adjourns

to FDA

From NDA

AG EN DA

Moderator:

Paul M. Weiss, Ph.D. Managing Director VentureInvestors LLC

to save the day.

We’re with you.

Ben Johnson, Sr. Relationship Manager Phone 952.745.1405 E-mail bjohnson@svb.com Jay McNeil, Managing Director Phone 952.745.1401 E-mail jmcneil@svb.com Silicon Valley Bank 1550 S. Utica Avenue South, Suite 700, St Louis Park, MN 55416 Phone 952.745.1400 svb.com ©2012 SVB Financial Group. All rights reserved. Member Federal Reserve System. SVB>, SVB>Find a way, SVB Financial Group, and Silicon Valley Bank are registered trademarks. B-12-12563. Rev. 11-13-12.

B_Healthcare Venture Forum_ Sponsorship Ad_Katrina Smith_111212_1e.indd 1

11/13/12 12:22 PM

CO-CHAIRS

Peter Kleinhenz Venture Partner - Fletcher Spaght Managing Director - CID

A DVIS O RY B OA R D

Peter Kleinhenz is a Venture Partner at FletcherSpaght Ventures and a Managing Director at CID Capital,Inc. He has been actively involved in life science-based businesses for over 25 years as an entrepreneur, consultant, and investor. Currently he represents Fletcher Spaght in two portfolio companies: Surgiquest, Inc. and Cayenne Medical, Inc. and represents CID in the following portfolio companies: Axiomed Spine, Inc., Celleration, Inc., Ekos, Inc., MedVantx, Inc., and RedPath, Inc. Peter invests in a broad array of life since opportunities with a special interest in medical devices and diagnostics. He joined Fletcher Spaght Ventures in 2009 and CID in 2001. Previously, Peter served as VP of Commercialization for Battelle Memorial Institute and as an independent consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups. Peter was CEO of Progenics.

Inc., a medical device design and manufacturing company and held a variety of senior executive positions at Neoprobe Corporation, a biotech and medical device company focused on cancer diagnostics and therapeutics, including CFO and Vice President of Product and Market Planning. Peter received an MBA from Case Western Reserve University, a Bachelor’s degree from Loyola University of Chicago, and is a Certified Public Accountant, Ohio. Peter is the founder and Chairman of the MidAmerica Venture Capital Forum.

Kathleen A. Tune Partner Thomas, McNerney & Partners Kathy joined Thomas, McNerney & Partners from Piper Jaffray, where she was a health care analyst focused on medical technology companies. While at Piper, Kathy covered over 20 companies in the medical device, medical supply and diagnostic areas. Her background also includes experience in new product development at Solvay, S.A. (in a division that is now part of Wyeth). Projects at Solvay included the development of vaccines for the prevention of viral infections. Kathy was also a Senior Scientist in molecular biology at the University of Minnesota, where she worked on the development of molecular biology based assays for the detection of infectious agents. Kathy is currently a board member of CAS Medical Systems, Inc. and VertiFlex, Inc. She is also a member of the Executive Leadership Team for the American Heart Association’s Go Red for Women campaign. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota’s Carlson School of Management, where she was a Robert and Gail Buuck Scholar.

Jack K. Ahrens General Partner TGap Venture Capital Funds

George Arida Managing Director Venture Investors, LLC George Arida is a Managing Director of Venture Investors LLC, focusing on Health Care investment opportunities. He served as Board Chairman for Nerites, Inc. until acquired by Kensey Nash (NASDAQ:KNSY) in January 2011, and also for Zystor Therapeutics, Inc. until ZyStor was acquired in August 2010 by BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). George also serves as Chairman of Celleration, and as a director on the Boards of Chromatin and NanoBio. George is a Founding Director of the Mid-America Healthcare Investors Network, and he guest lectures at the University of Chicago Booth School of Business and the University of Wisconsin School of Business. He also participates as a panelist for National Science Foundation SBIR grants in the areas of biotechnology, drug delivery, tissue engineering and repair, nanomaterials, membranes and separations technologies.

Prior to Venture Investors, George most recently served as CFO for a Chicago-based financial consulting and brokerage firm, and previously spent eighteen years in various management, marketing, technical sales and engineering positions at U.S. Filter Corporation, Betz Laboratories, Alar Engineering.

George has a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign and an M.B.A. with high honors from the University of Chicago.

A DVIS O RY B OA R D

Jack is a founding General Partner of TGap Venture Capital Funds, headquartered in Kalamazoo, Michigan. TGap I is a $20 million early stage, Midwest focused venture capital fund established in August of 2002 and TGap II is a $26 million fund established in 2008. Jack has been a venture capitalist and fund administrator since 1979; first as President of United Capital Corporation of Illinois (an SBIC), since 1983 as a General Partner of Pathfinder Venture Capital Funds I,II, III. Prior to that he had seven years of experience in bank trust investments and operations.

He became a Chartered Financial Analyst (CFA) in 1982 and has advanced training at the American Institute of Banking, NASBIC Management Institute, and Stanford Advance Management College. He has served on many Boards during his career including Afmedica, Inc., Central Data, Inc., Micro Business Applications, Inc., MedVantx, Inc., MinuteClinic, Inc., NeoChord, Inc., Vector General, Inc., Volunteer Health Plans, Inc. and he is the Chairman of the Great Lakes Entrepreneur Quest. He has been on several 501C3, Not for Profit Boards, and has held various officer roles in these organizations. He is a graduate of Indiana University.

Dan Broderick Vice President BioGenerator/BioSTL Mr. Broderick, is the Founder and President of the Global Agtech Investors Network GAIN), a not for profit corporation dedicated to supporting capital formation and innovation in agtech companies. He was responsible for GAINs original concepts and designed product offerings and value propositions.

As Vice President, Capital Formation and Entrepreneurship, at BIO St. Louis he is responsible for increasing the amount of early stage and follow on investment capital in the region. He is also overseeing the organizations efforts to recruit and train entrepreneurs and promotion of entrepreneurship in general. Mr. Broderick is also a Venture Partner at Prolog Ventures.

A DVIS O RY B OA R D

Mr. Broderick is actively involved in the venture capital community on a regional and national level. He served on the Board of Directors of the National Venture Capital Association (NVCA). He has testified before the U.S. Congress on behalf of the NVCA; works on a number of NVCA committees, and chaired the Research Committee. Mr. Broderick is the founder and President of the Mid-America Healthcare Investor Network (MHIN) an organization designed to promote venture investing in Mid America, currently MHIN has over 50 venture firms as members.

Doug Cameron Co-President and Director First Green Partners Doug Cameron is Co-President and Director of First Green Partners, an early-stage investment firm focused on companies with technology related to renewable and fossil carbon. Doug’s career has spanned business, finance, and academia, including positions at Khosla Ventures, Piper Jaffray, Cargill, and the University of Wisconsin-Madison. In 2009, Doug was the recipient of the prestigious Raphael Katzen Award for his contributions in furthering the deployment and commercialization of biotechnology to produce fuels and chemicals from renewable resources.

Doug graduated from Duke University with a Bachelor of Science in Engineering degree in Biomedical Engineering. He earned a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. Prior to attending MIT, he was the fourth employee of Advanced Harvesting Systems, an agriculture start-up company backed by International Harvester.

He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE), a Fellow of the Society of Industrial Microbiology (SIM), and a Fellow of the American Society for the Advancement of Science (AAAS). Doug is also a Consulting Professor of Chemical Engineering at Stanford University.

John Deedrick Managing Director Linn Grove Ventures Mr. Deedrick was a Founder and Managing Director of Accuitive Medical Ventures (AMV), an Atlanta-based venture capital firm. He was responsible for raising over $230 million in capital in AMV’s two funds. AMV has significant exits from LipoSonix, Sadra Medical, and SoftScope with numerous other companies approaching possible acquisitions or IPOs. From 1997-2003, he was a Venture Manager for Mayo Medical Ventures. Where he managed investments in several emerging healthcare companies including Exact Sciences (NASDAQ:EXAS), Circe Biomedical (acquired), Ascension Orthopedics (acquired), Neotonus (spin out created Neuronetics), CardiacAssist, Image-Guided Neurologics (acquired), Tomotherapy (NASDAQ:TOMO), Cerebral Vascular Applications, and Volcano Therapeutics (NASDAQ:VOLC).

In addition, he was instrumental in the start-up of four Mayo-founded companies: Santarus (NASDAQ:SNTS), Copharos, TeraMedica, and Torax Medical.

George Emont Managing Director Triathlon Medical Ventures George Emont is a Managing Partner with Triathlon Medical Ventures and a Managing Partner of the Kentucky Seed Capital Fund. Mr. Emont’s more than two decades of health care industry experience include 14 years in venture capital. Prior to joining Triathlon and KCSF, Mr. Emont was Director of Venture Capital for Humana Inc. where he managed a venture capital fund that made investments totaling over $75 million in 11 portfolio companies and three venture funds. Mr. Emont’s resume includes service with Baxter Healthcare Corporation and IAI Venture Capital Group, followed by the successful launch and eventual sale of oncology-focused biotechnology start-up OncoTherapeutics. Mr. Emont currently is on the boards of Celleration, Juventas Therapeutics, Pradama, ApoImmune, RhinoCyte, AllTranz and OrthoData. Mr. Emont is from Granville, Ohio, holds a B.A. from Oberlin College in Oberlin, Ohio, and an M.B.A. from the University of Chicago.

A DVIS O RY B OA R D

He is also Chairman, President and Founder of GreatDeeds, a Minnesota non-profit organization.

Mr. Deedrick received his BS in Business Administration from Northwestern College and his MBA from the University of St. Thomas.

Kevin Etzkorn Managing Director Heroncap Mr. Etzkorn brings over ten years of venture capital experience and more than thirteen years of operational and technical management experience to the Fund. Prior to joining Heron, Mr. Etzkorn was a Principal at CID Capital, a life science and technology venture fund.

While at CID, his portfolio responsibilities included: Axiomed Spine Corporation, Bridge Semiconductor Corporation, EKOS Corporation, HyperNex, Inc. (acquired by Nova Measuring Instruments) and Renal Solutions, Inc. (acquired by Fresenius Medical Care).

A DVIS O RY B OA R D

Prior to joining CID Capital in 2001, Mr. Etzkorn spent thirteen years in the U.S. Navy in a variety of technical and supervisory roles, most recently as a Nuclear Engineer and Communications Officer aboard the Fleet Ballistic Missile Submarine USS ALASKA, where he was responsible for the establishment and management of its Information Technology Department. He also served as an Assistant Professor in the Department of Naval Science at the University of Illinois. Mr. Etzkorn has served as an advisor to the National Science Foundation for the Small Business Innovation Research (SBIR) Program and as an advisory board member for the Telemark Group, a New York based investment fund. He received his M.B.A. from the University of Illinois and a bachelor’s degree in Electrical and Computer Engineering from the University of Wisconsin.

Mr. Etzkorn led Heron’s investments in AirXpanders, Celleration and BioSET, Inc. He also led the firm’s investment in Atlantis Components, Inc. which was sold to Astra Tech AB, a subsidiary of AstraZeneca, in 2007.

Jodi Hubler Managing Director Lemhi Ventures Jodi Hubler is Managing Director of Lemhi Ventures a healthcare services fund investing in disruptive change business models. Jodi’s career includes executive experience in a wide range of companies, from international recruiting at Cargill and a vice presidency in a $2 billion division of Alcoa, to the controlled chaos of a venture-backed start-up when she served as Chief People Officer for Definity Health.

Jodi holds MAIR and BBA degrees from the Henry B. Tippie College of Business at the University of Iowa. With a deep background in strategic human capital development and nearly a decade of operational experience, she is an active advisor to the leaders of several portfolio companies. She served on the boards of Carol Corporation, DNA Direct, and Liazon Corporation. Jodi currently serves on the boards of DRX and Recondo Technology, and is chair of the board of OneHealth Solutions, Inc.

Chris Hoffmann Senior Director & Chief Marketing Officer TripleTree Chris Hoffmann is a Senior Director, focused on leading the firm’s research, marketing and executive programs. As the author and editor of numerous research publications, his specialization spans across all of the sectors covered by the firm. He offers significant experience as an operating executive, analyst, and entrepreneur in the technology industry.

Prior to TripleTree, he served as President and Chief Operating Officer at Tier1 Research, an independent sell-side research firm where he led the firm to an acquisition by The 451 Group.

Before Tier1 Research, he held executive positions at Gartner, GE Capital Consulting, IBM Global Services, and a consulting firm which he founded. He is a frequent presenter at industry events and has been quoted in numerous publications including the Wall Street Journal, the New York Times and CNN Money.

Kristin Myers Principal Arboretum Ventures Kristin Myers joined Arboretum Ventures in 2012 as a Principal and is responsible for sourcing and leading new investment opportunities as well as supporting existing portfolio companies.

Previously, Kristin worked at Skyline Ventures in Palo Alto, CA starting in 2008 where she sourced and led new investment opportunities and supported portfolio companies. She served on the Board of Directors at Medivance, a therapeutic cooling company, before its acquisition by Bard in 2011 and supported multiple new investments including SI Bone, an orthopedic company, where she was a board observer.

Prior to her investing experience, Kristin spent nearly 7 years working in the medical device industry, specifically focused in cardiology. She spent 5 years working in Medtronic’s Cardiac Rhythm Management division first in product development, then in marketing and then in sales in New York City. Previous to her time at Medtronic, Kristin worked for Guidant’s Drug Eluting Stent division (now Abbott), Guidant’s Cardiac Rhythm Management division (now Boston Scientific) and for Abiomed’s Total Artificial Heart program. She has authored multiple patents during her career.

Kristin earned a BS in Biomedical Engineering from the University of Wisconsin-Madison and an MBA from Harvard University.

A DVIS O RY B OA R D

Chris earned a B.B.A. degree in Marketing from the University of Minnesota-Duluth. In addition, he has completed advanced studies at the University of Minnesota and Michigan State University.

Jayant Parthasarathy Director, Innovation and R&D UnitedHealth Group

A DVIS O RY B OA R D

Jayant Parthasarathy (JP) started his career in healthcare designing nano-sensors and wireless chipsets to better understand neuronal functioning and aid Alzheimer’s research.

JP applied his understanding of sensor and wireless technology to design award-winning products at Nonin Medical Inc. to aid patients suffering from chronic cardio-pulmonary diseases. With a keen interest to commercialize his group’s inventions, he also launched the eHealth Business segment at Nonin to serve a global market in chronic respiratory care.

As Chair of the Technology Group at the Continua Health Alliance, JP led a world-wide group of architects from Fortune 50 companies and start-ups alike to develop industry-first guidelines to promote interoperability, improved care co-ordination and reduce integration costs for systems designed to aid personal health & fitness, chronic disease management and facilitate independence for an aging population. Currently, as Director of the Innovation, Research and Development group at UnitedHealth Group, JP’s team led the concept and development of a comprehensive health management platform integrating social and mobile technologies, biometric devices, advanced analytics to discern crowd-sourced behavioral patterns and live coaching elements. He is working on emerging business concepts that aim to disrupt healthcare delivery as it is practiced today and significantly improve access to high quality and cost efficient care. JP attended Purdue University and the University of Minnesota, where he received his Doctorate in Engineering.

J.P. Peltier Managing Director Piper Jaffray J.P. Peltier is a Managing Director and member of the Piper Jaffray health care investment banking team. Peltier has 13 years of investment banking experience at Piper Jaffray focused exclusively on the medical technology sector. Peltier provides medical technology clients with a full range of investment banking services from equity and debt financing to mergers and acquisitions advisory.

Peltier’s prior experience includes five years at HomeServices of America, a Berkshire Hathaway subsidiary, where he served in a M&A advisory role and led the mortgage banking division.

Peltier graduated from the University of St. Thomas and received a Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University.

Nathan L. Stacy Investment and New Ventures Director Mayo Clinic Ventures

Dale Wahlstrom President & CEO Life Science Alley and BioBusiness Alliance of Minnesota Dale retired from Medtronic in 2006 after 24 years. Most recently he served as V.P. of CRDM Venture Programs. Prior to this he served as V.P./G.M. of the CRDM Therapy Delivery business.

Before Medtronic, he held management and sales positions at Litton Microwave and Burroughs Corporation and managed a clean technology start-up company.

Today, he serves as the President and CEO for LifeScience Alley and The BioBusiness Alliance of Minnesota. Dale is currently a member of several industrial advisory and governance boards for different universities and companies. In 1988, he was a recipient of the Medtronic Star of Excellence Award, and in 1997 received the Wallin Leadership Award. In 2002, Dale was recognized as the outstanding graduate of the year by the engineering department of St. Cloud State University.

In 2007, he was honored by Twin Cites Business Magazine and was the recipient of the Bioscience Success Story Award. In 2010, Twin Cities Business Magazine selected Dale as one of 200 “Minnesotans You Should Know.� He currently has eleven patents in medical device technology with more pending.

Dale received his M.S. in Manufacturing Systems Engineering from the University of St. Thomas in 1994, and his B.S. in Engineering and Technology from St. Cloud State University in 1978.

A DVIS O RY B OA R D

Nathan L. Stacy works for Mayo Clinic, where he is responsible for commercializing Mayo Clinic technologies through new company creation and venture capital investing. He leads and manages investments in medical device, biopharmaceutical, diagnostic, and healthcare IT companies and serves as an observer or director on company boards. He has over seventeen years of broad-based health care business and policy experience within Mayo Clinic, the health care industry, and the public sector. He received his A.B. in economics and public policy from Duke University and his M.H.A from the University of Washington.

S P EA K ER B IO G R A P H IES

John Banta CEO & Managing Director IllinoisVENTURES LLC John Banta serves as the CEO & Managing Director of IllinoisVentures, LLC, a premier seed and early-stage technology investment firm focused on starting and building globally-competitive companies based on research conducted at Midwest Universities and federal laboratories. Conceived and launched by the University of Illinois, the firm is consistently named by Entrepreneur magazine to its national list of the top 100 venture capital firms. John also serves as the Managing Partner for the Illinois Emerging Technologies Funds managed by the firm. John is the former President and COO of DigitalWork, Inc., a Draper Fisher Jurvetson, TL Ventures and Dell Ventures portfolio company, having served previously as its Senior Vice President of Corporate and Business Development. Prior to DigitalWork, John served as Vice President of Corporate Services for UBS, and as a member of the Board of Directors of the Investment Management Consultant’s Association. John works with a wide variety of portfolio companies, with an emphasis on clean technologies including renewable fuels and chemicals, water, and agriculture and serves as a Director on behalf of numerous portfolio businesses, as well as the Board of Directors of the Illinois Venture Capital Association, the iBio Institute, the Argonne Venture Accelerator Consortium and the Initiative for Sustainability and Energy at Northwestern University. John earned an MBA in Finance and Statistics with high honors from the University of Chicago Graduate School of Business where he has been a frequent guest lecturer, and a Bachelor’s Degree in Finance from the University of Illinois College of Commerce.

Brian Bischoff CEO HealthSense Brian J. Bischoff- Co-Founder, President & CEO of Healthsense, Inc. is an acknowledged leader in the field of product development and application of sensing and control technology. He has had the privilege of being the principal investigator on three National Institute of Health (NIH) and two Defense Advanced Research Projects Agency (DARPA) grants directed at technology enabled care.

He has been developing and commercializing new products for 24 years and holds twelve patents. His career has included key leadership positions with Emerson Process Management and Honeywell, where he was selected as one of thirty-three global executives to participate in the Vision 2005+ project to define strategic trends that would shape the company and society over a five to ten year horizon.

Following the Vision 2005+ project, he managed the large, global, Control Products business unit for Honeywell, making significant operational improvements.

Brian holds Bachelor of Science and Master of Science degrees in Mechanical Engineering from the University of Minnesota.

Julie Brewer Vice President, CVG Strategies Medtronic Julie has over 20 years of experience in healthcare sales with the last 17 years in positions of leadership. Julie joined Medtronic in 2006 as the Eastern Area Vice President for Medtronic Cardiac Surgery. Since that time, Julie has held various sales leadership positions with Structural Heart including the Vice President of Sales. In May 2011, as part of the creation of the Cardiac and Vascular sales organization, Julie was asked to lead the creation of the Strategic Sales team for the Cardiac and Vascular Group. In this role, she and her team lead the strategy for our most critical accounts and integrated delivery networks across the country. The primary focus is to evolve from a transactional, product focused approach with a physician customer to a more “solutions based” approach with physicians, administrators and payors.

Julie received her Bachelor of Science in Business Administration from the University of Illinois at Urbana-Champaign. She is a founding member of the ASPIRE Women’s Field Resource Group at Medtronic and has participated in the Medtronic Global Leaders Program.

Julie is married and resides in Medina, MN. She and her husband, Patrick have 3 children – Ryan (17), Evan (15) and Allison (11).

James Burgum Co-Founder Arthur Ventures James Burgum is the Co-Founder of Arthur Ventures, a venture capital firm located in Fargo, ND. The firm’s first fund, launched in July of 2008, is a mission driven fund that seeks to seed and enable growth in its partner companies. James’ experience includes angel investing, venture capital, government policy, international trade, agribusiness and entrepreneurship. He has spent nearly a decade in these various activities and continues to be active in driving economic growth in his home state of North Dakota and the surrounding region. Previous work engagements have included business development roles at Great Plains Software, Microsoft, Student Body President of North Dakota State University, the Office of the Governor of North Dakota, the North Dakota Trade Office, and Advenio Partners – a consulting firm that participated in angel investments and turn-around projects. While working for the state of North Dakota, key initiatives James was involved in starting and launching such as Operation: Intern, the North Dakota Trade Office, and Young Professional Networks remain strong programs of the state’s efforts to grow and diversify the economy. Currently James serves as Managing Director of Arthur Ventures which is focused on investments in early-stage companies; in that capacity he serves on the Board of Directors at Intelligent InSites Inc., Workface Inc., AltraVax Inc., and Loyalty Builders, Inc. James also serves on the board of Arthur Companies Inc., a diversified agri-business.

S P EA K ER B IO G R A P H IES

Prior to Medtronic, Julie was the Vice President of Sales for Asteres Inc., a start up organization focused on technology to automate medication delivery to consumers. Prior to Asteres, she held various leadership positions at McKesson, Inc. including Regional Vice President for McKesson Automated Healthcare and Vice President of Sales for McKesson Automated Prescription Systems.

Julie’s healthcare sales career started at Allergan, Inc as a territory manager in Houston, TX and then as a district manager for the Midwest Division.

S P EA K ER B IO G R A P H IES

David Cassak Vice President, Content, Managing Director, Medical Devices Elsevier Business Intelligence David Cassak is a Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company. He has been involved with the health care industry for more than 30 years and writes extensively on the medical device industry for Windhover’s IN VIVO and Start-Up. He is also a frequent speaker before various companies and industry trade groups. Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other publications, including Start-Up: Emerging Medical Ventures,™ and The RPM Report: Regulation • Policy • Market Access.™ In 2004, Windhover acquired Medtech Insight Inc., and now publishes the Medtech Insight: Medical Technology Market Intelligence™ newsletter. In addition, Windhover also created the Strategic Intelligence Systems, a web-based suite of databases, featuring the most comprehensive and detailed source of industry alliances, acquisitions and financings. SIS is unique among databases in providing expert commentary and analysis along with data. Windhover/EBI also produces numerous conferences, including the Investment in Innovation (In3) medical device partnering conferences around the world, as well as such pharma-focused conferences as the Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover meetings. and it also offers a wide range of market research reports under its Medtech Insight imprint. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and FDC Reports, publishers of The Gray Sheet and The Pink Sheet, among other leading industry newsletters.

Michael D. Dale President & CEO Medical Device Innovations, Inc. An accomplished Medical Device Executive, Michael Dale has more than 25 years of experience as a leader in both early and late stage development companies. Most recently Mr. Dale served as Chairman, President and CEO of publicly traded ATS Medical until its acquisition by Medtronic in 2010.

During his eight-year tenure at ATS, he spearheaded the company’s reorganization and resurgence, helping ATS establish itself as a leader in the surgical treatment of heart valve disease and atrial fibrillation. Under his strategic guidance, ATS experienced significant expansion in market capitalization, from $7.5 million to more than $375 million. Mr. Dale’s medical device industry experience spans cardiovascular, neuromodulation and electrophysiology markets.

In addition to his work with ATS Medical, Mr. Dale has held executive leadership roles with Endocardial Solutions, Cyberonics, St. Jude Medical and Edwards Life Sciences.

He currently serves on the Board of Directors of Philadelphia-based Neuronetics, Inc., Rhythmia Medical in Boston, and Preceptis Medical of Minneapolis. Mr. Dale holds a Bachelor of Science degree from California Polytechnic State University in San Luis Obispo, California.

William Faulkner CEO Ascenix Biotech Bill Faulkner is an active entrepreneur and investor. He is currently Chairman and CEO of Ascenix BioTechnologies, an early stage industrial biotechnology firm. He is also Chairman of Hennepin Life Sciences, a pharmaceutical company focused on alternative antibiotics for human and animal health applications. In addition to his experience in the life sciences, he has been heavily involved in advanced materials and the energy market, focused on generation and services.

Bill spent his early professional career as a nuclear engineer in the Navy and as a founding employee in a number of high technology businesses, helping to move them through multiple growth stages and financing events. He has served on several charitable and professional boards in addition to the professional boards for his companies, including BPI (an energy development company) as well as on the Board of Trustees of the University of Dallas and Annual Fund Advisory Board for the University of Chicago.

Dr. Jeremy Friese Founder and CEO, Evidentia Health Medical Director for New Ventures and Business Development in the Center for Individualized Medicine and Associate Chair of Finance in the Department of Radiology, Mayo Clinic Dr. Friese is an interventional radiologist at Mayo Clinic in Rochester, Minnesota. His clinical and research focus includes minimally invasive vascular disease and cancer. He serves as Medical Director for New Ventures and Business Development in the Center for Individualized Medicine and as Associate Chair of Finance in the Department of Radiology. He is past chair of Novation’s imaging council and currently sits on the cardiovascular council. Dr. Friese is Co-Founder of Evidentia Health (a seed-stage HIT company), an active angel investor, and board member for SV Biosystems, Inc. He earned an M.D. from Mayo Medical School and an M.B.A. from Harvard Business School where he collaborated with Professors Clay Christensen and Michael Porter.

S P EA K ER B IO G R A P H IES

Bill graduated from the University of Dallas with degrees in physics and economics in addition to playing varsity basketball. He received an MBA from the University of Chicago Booth School of Business in finance and economics, where he was awarded the Dean’s Award of Distinction.

Mark Gehring Co-Founder & President Asthmapolis Mark Gehring is Co-Founder and President of Asthmapolis, a company dedicated to improving asthma control and reducing cost using medication sensors and mobile apps.

S P EA K ER B IO G R A P H IES

He has previously served as CEO of three companies: Geometrics, developer of the first commercial 3D radiation treatment planning system, now marketed by Philips and used to plan 25% of the radiation treatments worldwide since the mid-90’s; UltraVisual, a medical imaging (PACS) startup that merged with another startup, Emageon, reached $100M in sales, and went public in 2005; and Sharendipity, a software development environment for non-programmers.

J. Thomas Halverson, Jr. Managing Director and Group Head Clean Technology & Industrials Piper Jaffray & Co. Tom Halverson is a managing director and co-head of the Piper Jaffray clean technology and industrials investment banking group. Halverson’s transaction experience includes numerous exclusive sale mandates, buy-side advisory services, leveraged buyouts, divestitures, fairness opinions, defensive advisory assignments and public and private offerings of debt and equity securities for a wide range of clients, including private equity groups, public companies and privately owned businesses.

Prior to joining Piper Jaffray, Halverson worked in private equity and as a corporate strategy consultant.

Halverson graduated from Harvard College and received a Master of Business Administration degree from the Darden Graduate School of Business at the University of Virginia.

Mark Heesen President National Venture Capital Association (NVCA) For more than two decades, Mark Heesen has advocated for the venture capital industry, entrepreneurship and innovation, first as NVCA’s head of public policy and, since 1999 as the Association’s president. Under his leadership, the NVCA has grown in both scope and scale, broadening its public policy agenda, expanding its research initiatives, and adding member programs. By providing strategic direction for the NVCA professional staff and managing a board of more than two dozen venture capital practitioners, Mark sets the legislative and regulatory agenda for issues relating to information technology, life sciences and clean technology investing.

As the primary spokesperson for the venture capital industry, Mark is often called upon by the financial media, NVCA members, limited partners, and regional associations to offer insights and perspectives on trends and developments occurring within the asset class. He is a frequent presenter at industry conferences, a familiar and trusted source in news articles focusing on the venture industry, and a recurrent guest on financial broadcast news programs.

Prior to his work at NVCA, Mark was an aide to a former Governor of Pennsylvania and was Deputy Director for Federal Funds reporting to the Texas Legislature. Mark received a law degree with an emphasis in taxation from the Dickinson School of Law in 1984.

Eric W. Kaler, Ph.D. President University of Minnesota When Eric Kaler took office on July 1, 2011, he became only the second alumnus to rise to the position of University of Minnesota President.

In his first year on the job, President Kaler emphasized his commitment to academic excellence and rigor by investing in new faculty positions.

He committed to keeping the University accessible to students of all economic backgrounds by increasing financial aid and setting the smallest tuition increase this century.

He stressed the importance of the University’s groundbreaking research enterprise. He aggressively reached out to Minnesota’s corporate and investor communities, and he worked to bring the University’s discoveries more swiftly to the marketplace. And he did so even as he led the University in efforts to contain costs, operate more efficiently and effectively, and to demonstrate exceptional stewardship of public and tuition dollars.

President Kaler received his Ph.D. in Chemical Engineering from the University in 1982. He went on to become one of the nation’s foremost experts on “complex fluids,” which are used in many applications, including drug delivery, food processing, pharmaceuticals, and many manufacturing processes.

Before coming to the ‘U,’ Kaler served from 2007 to 2011 as Provost and Senior Vice President for Academic Affair s at Stony Brook University in Stony Brook, N.Y. He previously was Dean of the University of Delaware’s College of Engineering. He also taught at the University of Washington.

He received his undergraduate degree from California Institute of Technology.

President Kaler and his wife, Karen, have two adult sons.

S P EA K ER B IO G R A P H IES

Mark has successfully led the NVCA through Dodd-Frank financial reform, threats to established tax policies, SBIR re-authorization, and patent reform. He continues to work with his staff to improve the FDA regulatory approval process, highly skilled immigration policy, and energy reform.

A staunch advocate for policies that support America’s entrepreneurial ecosystem, Mark supports funding for basic research and ongoing incentives for long-term investment in start-up companies.

Steven C. Kuemmerle Head, Venture Investments Abbott Biotech Ventures, Inc. As Head of Venture Investments, Abbott Biotech Ventures, Inc. (ABVI), Steve is responsible for leading the evaluation and execution of equity investments in emerging pharma and biotech companies of strategic interest to Abbott. From November 2002, until joining ABVI, Steve served in Abbott’s Global Pharma Licensing Group. Steve first joined Abbott in 1987, where he managed several clinical diagnostic R&D units. In 1997, he moved to the Pharmaceutical Division, entering the Technology Licensing Group and in December of 1998, was appointed director of that unit. From 2000-2002, Steve was director of the then new Abbott Decision Support Group (DSG), which leads projects applied to pharmaceutical product development strategic decision-making and portfolio analysis.

S P EA K ER B IO G R A P H IES

He received his B.S. in Biochemistry from Michigan State University in 1976 and went on to become an analytical chemist for The Upjohn Company from 1977-1981. He received his Ph.D. in Biochemistry and Molecular Biology from Northwestern University in 1988.

Julia C.Owens, Ph.D. Founder & Chief Executive Officer Atterocor, Inc. Dr. Owens is a biotech entrepreneur with an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Atterocor, she served as Senior Vice President, Corporate Development and Strategy at Lycera Corp. where she led the partnering process that led to Lycera’s major research partnership with Merck & Co. She also acquired a new platform discovery program for the company and negotiated its partnership with the University of Michigan moving the company to the North Campus Research Complex. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals. She also worked at Tularik Inc. (now Amgen SanFrancisco) in business development, where she led partnering for the oncology and immunology areas. Dr. Owens began her business career at the University of California, San Francisco Office of Technology Management. Dr. Owens has a Ph.D. in biochemistry from the University of California, San Francisco a B.S. in Chemistry and a B.A. in Molecular and Cellular Biology from University of California, Berkeley.

Robert Plourde Vice President, Innovation and R&D UnitedHealth Group As part of the UnitedHealth Group Innovation and R&D team, Mr. Plourde has accountability for defining and delivering innovation opportunities across UnitedHealth Group’s business segments. In this role, he is expanding the use of technologies to the many constituents in the health care sector including consumers, providers and employers. He is currently accountable for driving the vision and strategy for integration of gamification into the consumer, provider, and employee engagement platforms.

Prior to joining UnitedHealth Group, Mr. Plourde spent 15 years with Accenture as a Senior Executive within Accenture’s Management Consulting team. He has worked across with broad range of clients across financial services, retail, industrial products, telecommunications, media and entertainment, and industrial products. During this time, he was accountable for defining and delivering on business and technology strategies which advanced customer engagement through innovation.

Stan Rose, Ph.D. Chief Commercial Officer Nabsys

Barbara Lano Rummel Partner Lindquist & Vennum, LLP For more than 20 years, Barb Rummel has counseled boards of directors, executive officers and owners of public and privately held businesses in making critical business decisions involving strategic objectives, corporate finance, and mergers and acquisitions. Known for her integrity and dedication to the success of the business she works with, Barb endeavors to keep clients’ business objectives at the forefront of every matter.

Barb has completed numerous M&A transactions involving public and privately held businesses. These deals have ranged in transaction size from under $10 million to over $1 billion. Her experience covers various industries, with particular emphasis on the life sciences, including medical device, pharmaceutical, and biotechnology companies.

Her extensive experience with initial public offerings and securities laws affecting publicly-held corporations enables Barb to competently manage complex governance issues.

Barb currently serves on the firm’s management committee and is past chair of the firm’s Life Sciences industry group. She also represents Lindquist & Vennum within TAGLaw, an international network of over 150 independent law firms in 100 countries, and recently served on the TAGLaw Advisory Board. Barb was a member of the American Bar Association’s House of Delegates from 1989-1990.

Barb’s community involvement has included a five-year tenure on the board of directors for the Hope Chest for Breast Cancer Foundation, an organization dedicated to fighting breast cancer and serving people affected by it.

S P EA K ER B IO G R A P H IES

Stan Rose is a Ph.D. biologist, seasoned biotechnology executive, and serial entrepreneur.

He is President of Rose Ventures, Inc., a firm that provides consulting and directing to select clients in the life science research products space, and manages a portfolio of public and private equity investments. Highlights from his 20+ year career in the genomics research products business include serving as CEO of NimbleGen Systems, a microarray products company, from 2003 through its acquisition by Roche in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s. Dr. Rose currently serves as Director and Chief Commercial Officer of Nabsys (Providence, RI); Director of Cellular Dynamics International (Madison, WI); and Director of Inverna (Madison, WI). He chairs the Market Advisory Board for Cyvek (Wallingford, CT), is a Technical Advisor to McLane Research Laboratories (Falmouth, MA), and is a Member of Tactics II SC Management LLC (Madison, WI). Dr. Rose received his B.A. from Cornell University and his Ph.D. from the Massachusetts Institute of Technology.

Baiju R. Shah Chief Executive Officer BioMotiv

S P EA K ER B IO G R A P H IES

Baiju R. Shah is CEO of BioMotiv, the for profit therapeutic accelerator that is a part of The Harrington Project for Discovery & Development. Prior to BioMotiv, Mr. Shah was President and CEO and a Founder of BioEnterprise, a partnership of Case Western, Cleveland Clinic, Summa Health, and University Hospitals. BioEnterprise is a business acceleration initiative to support the growth of bioscience companies. During Mr. Shah’s tenure, it helped more than 110 Cleveland companies that collectively attracted $1.3 Billion in new funding. He started his business career at McKinsey & Company. Shah serves on the Board of Invacare and on the Regional Advisory Board of RBS Citizens. In the community, Shah is Chair of Global Cleveland and also serves on the Boards of Great Lakes Science Center, Saint Luke’s Foundation, and United Way. He has also served as the founder and Chair of TiE Ohio and Summer on the Cuyahoga. Shah has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland’s most influential leaders. Shah received a J.D. from Harvard and his B.A. from Yale.

David Van Sickle CEO Asthmapolis David Van Sickle, Ph.D. is the Co-Founder and CEO of Asthmapolis, a Madision, WI based company that is pioneering effective new disease management solutions for asthma and chronic respiratory disease. Previously, Van Sickle was a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. From 2004-2006, he was an Epidemic Intelligence Service officer at the Centers for Disease Control and Prevention in Atlanta, where he was assigned to the Air Pollution and Respiratory Health Branch. Van Sickle received his Ph.D. in Medical Anthropology from the University of Arizona in 2004. In 2011, he was named a Champion of Change by the White House for his work on innovation.

Diana Twyman Business Development Executive Integrated Project Management Diana Twyman is the food and ag industry Business Development Executive for Integrated Project Management. She has over 20 years of marketing, commercial development and business management experience in the Food & Beverage and Life Science industries including North American Business Unit Manager for Nestle Medical Nutrition, Vice President of Commercial Development and Healthcare Marketing for Monsanto’s Nutrition and Consumer Sector, and Executive Vice President of Marketing, Business Development and Strategy for Miicro, Inc.

Dave Wagner Vice President, External Partner Development General Mills, Inc. Dave Wagner leads the External Partner Development effort for General Mills. In this role, he oversees external sourcing support to General Mills’ indirect spending, and chairs the company’s Supplier Partnership Board. His team also creates growth partnerships for the company’s marketing and innovation communities.

Dave has served at General Mills for 15 years. During this time, he has led sourcing strategies across the scope of sourcing operations. With a foundation in commodity, ingredient, packaging and indirect services categories, he moved into leadership positions as Director of Sourcing Operations for the Yoplait, Pillsbury and Baking Divisions.

Since 2004, Dave has led Strategic Sourcing for Marketing Services, and in 2006 was named Director, Strategic Sourcing and External Partner Development, which included all inbound and outbound licensing efforts.

Since 2008, XPD has been building capacity to develop and manage external alliances, and to source external innovation in support of GWin (General Mills Worldwide Innovation Network), GMI’s open innovation initiative.

Prior to working for General Mills, Dave served for 8 years as a Military Intelligence Officer in the United States Army in a variety of strategic and operational roles in the US and Europe.

Dave currently serves as Secretary to the Board for PPL Industries, a non-profit organization that provides education and job training to heads of at-risk, low income families.

Dave has an M.B.A. in Strategic Management from the University of Minnesota and a B.A. in International Relations from Auburn University. He lives in Eden Prairie with his wife Christa and three sons.

S P EA K ER B IO G R A P H IES

Ms. Twyman has successfully launched and managed over a dozen new products and business platforms based upon proprietary nutrition and diagnostic technology, and is co-inventor on 7 issued patents.

Paul M. Weiss, Ph.D. Managing Director VentureInvestors LLC Paul joined Venture Investors in 2006, as a Managing Director. He focuses on making Healthcare investments and is an active member in the firm’s Venture Igniter program.

S P EA K ER B IO G R A P H IES

Paul has over 20 years of operating experience in the biotech and pharmaceutical industries.

He previously was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma Solutions). Before joining Gala, Paul served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure and was subsequently acquired by Johnson & Johnson. Earlier in his career, Paul worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, a division of American Home Products (Wyeth is now part of Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs (SPL), a division of American Home Products, prior to its spin-out. Paul began his career in industry as the Director of Operations for Columbia Research Labs (Nasdaq: COB), a small, publicly-held company that focuses on women’s health.

Paul is currently a member of the Board of Directors for Akebia Therapeutics (also includes Aerpio Therapeutics), Euthymics Bioscience (also includes Neurovance and EBI Life Sciences), Mithridion, and ProCertus (also acting President and CEO). He is also an observer for Tissue Regeneration Systems and Inviragen. In addition Paul serves on the Board of Directors for Tamir Biotechnology, Inc. (formerly Alfacell Corporation, Nasdaq: ACEL), the Waisman Center Board of Visitors, and the Waisman Center Biomanufacturing Facility Advisory Board.

Paul received a B.S. in Biochemistry with honors from Carleton University-Ottawa, Ontario, a Ph.D. in Biochemistry and an MBA from the University of Wisconsin-Madison, where he also worked as a postdoctoral research associate.

John West Founder & Chairman The Whistle John West is a successful entrepreneur who has started, grown and sold two companies and is the Founder & Chairman of The Whistle. John was previously the CEO and Founder of Silver Oak Solutions, a spend management solutions business; and Enstrat, an environmental services company. John is on the Board of the Harvard Alumni Association, and is the former president of the Harvard Alumni Entrepreneurs Association. He has a BS Engineering from WPI and an MBA from Harvard Business School.

Greg B. Young Managing Director Burril & Company

S P EA K ER B IO G R A P H IES

Greg joined Burrill & Company in 2000 and has been primarily involved in sourcing, evaluating and investing in new business opportunities as part of the firm’s venture activities. His focus areas of investment cover green technologies and businesses addressing energy, climate and sustainability markets. He also acts as an investment manager for the Malaysian Life Sciences Capital Fund (MLSCF), a venture fund co-managed by Burrill & Company. Greg currently serves on the Board of HCL CleanTech and is a Board Observer on the Boards of Akermin and GloriOil. Greg was instrumental in sourcing and consummation of Burrill & Company and MLSCF’s investment in Gevo. Previously, Greg worked as a molecular biologist focused on protein expression at an early-stage biotech company located in San Diego. Greg received his BS in Biochemistry and Cell Biology from the University of California, San Diego and an MS in Biotechnology and Business from Northwestern University.

INVESTING IN INNOVATION

www.capitalroyalty.com

GE Capital Healthcare Financial Services

LIKE A BANK: WE MAKE HEALTHCARE LOANS. UNLIKE A BANK: WE KNOW THE COMPLEXITIES OF HEALTHCARE. At GE Capital, we’re not just bankers, we’re builders. Enhancing the quality of life is the mission of the healthcare industry. Supporting the growth of innovative life science companies, large and small, as a reliable source of essential financing is our mission at GE Capital, Healthcare Financial Services. With in-depth industry experience and expertise, our dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Stop just banking. And start building.

For more information call Joseph Hammer at 312-914-3166 or visit www.gecapital.com/healthcare34 .

© 2012 General Electric Capital Corporation. All rights reserved. All transactions subject to credit approval by GE.

The law firm of Dorsey & Whitney is a proud sponsor of the 10th Annual MidAmerica Healthcare Venture Forum Serving innovative companies and their investors for 100 years

www.dorsey.com

LINDQUIST & VENNUM Since 1968, Lindquist & Vennum has provided medical technology and life sciences companies--from early startups to multi-national public corporations--with a comprehensive array of legal services. We regularly counsel clients in: • Corporate structuring and financing; including both private and public financings •

Complex transactions, including mergers and acquisitions, joint ventures, and other strategic arrangements

•

Domestic and international pharmaceutical and medical device development, manufacturing, licensing, and distribution

•

Federal and state regulatory and compliance matters

S P O N S O R P RO F ILES

With a keen understanding of the industry, Lindquist & Vennum attorneys help health care clients achieve their business objectives quickly and economically.

KPMG KPMG LLP has maintained a continuous commitment to providing leadership, integrity, and quality service to the Twin Cities’ markets since 1904. We offer clients, emerging to FORTUNE 500 companies, the scale, global reach, industry insights, and multidisciplinary range of services they demand.

How we can help Our services help to address the interrelated set of needs that companies have on their journey to leadership. Each of our services draws upon the knowledge, experience, and networks of KPMG and brings them to the start-up and early-stage companies in a timely and cost-effective manner.

ARMENTUM PARTNERS LLC Armentum Partners is an independent financial services firm focused on providing capital raising and merger & acquisition advice to healthcare and technology companies.

Armentum primarily focuses on providing debt solutions that are aimed at servicing the non-dilutive working and growth capital needs of its clients while optimizing capital structure. Armentum works for both public and private companies, private equity investors, venture capitalists, specialty-focused funds and Boards of Directors. Armentum’s principals have collectively closed over 200 transactions and draw on their experience gained from working in investment banking, corporate finance, strategic advisory, commercial banking, business development, engineering and research.

For more information contact Chris Carthy at chris@armentumpartners.com or (415) 412-7421.

CAPITAL ROYALTY LP Capital Royalty is a market pioneer and innovator in healthcare investing that focuses on investments in FDA-approved products through royalty bonds, structured debt, revenue interests and traditional royalty monetizations. We target investments between $20 and $100 million and work directly with leading healthcare companies to provide customized financing structures to meet their unique needs. Our primary source of collateral is derived from commercialized products. As the only investment team with experience in structuring royalty bonds, structured debt and traditional royalty monetizations, Capital Royalty is uniquely qualified to meet a broad range of financing needs for healthcare companies.

D O R S E Y & W H I T N E Y LLP Celebrating its 100th anniversary, Dorsey & Whitney LLP in an international law firm with over 550 lawyers in 19 offices. Dorsey serves a wide range of industries in all areas of business law, with a strong emphasis on life sciences and health, as well as the investors who help companies fulfill their promise. Dorsey’s clients include innovators, providers, payers and investors, giving the firm insight into the many perspectives that make up the healthcare industry universe. Our Venture Capital and Emerging Companies Practice Group consists of over 80 lawyers dedicated to the needs of growing businesses.

EvaluatePharma® USA, Inc. Company Contact: 15 Broad Street Debbie Paul Suite 401 CEO, Americas Boston, MA 02109 E-mail: debbiep@evaluatepharma.com Tel: 1-617-573-9450 Tel: 1-617-573-9453 www.evaluatepharma.com

GE CAPITAL, HEALTHCARE FINANCIAL SERVICES With in-depth industry experience and expertise, the Life Science Finance team at GE Capital, Healthcare Financial Services has worked with more than 500 companies and provided over $2.5 billion in financing. As a reliable source of essential financing, our team of professionals creates business and financial solutions tailored to support the growth of innovative life science companies.

For more information, visit www.gecapital.com/healthcare.

HOPEN LIFE SCIENCE VENTURES Hopen Life Science Ventures invests in exceptional early-to mid-stage life science opportunities.

We are very active in the Midwest, a market traditionally under-served with capital. Our team consists of professionals with extensive senior leadership experience in public and private life science companies. We apply our scientific and business insights along with a proven resource network to enhance the development of our portfolio companies. www.hopenls.com

NAMSA NAMSA has provided services to medical device manufacturers for 45 years specializing in material safety testing and consulting. Through acquisition, NAMSA added comprehensive regulatory and quality systems support, expanded functional studies with state of the art imaging capabilities, full clinical research services with contract field clinical engineers, and expanded educational services including physician and sales training.

NAMSA continues to enhance medical product development by guiding inventors and manufacturers on the most efficient path to commercialization.

S P O N S O R P RO F ILES

EVALUATEPHARMA® EvaluatePharma® announces the solution for professionals who need the latest information on the Medical Device and Diagnostic Industry: EvaluateMedTech. Based on EvaluatePharma®’s proven platform, it delivers a one-stop source for up-to-date data and analysis. Visit us in booth 223/225 for a demo and complimentary report: EvaluateMedTech World Preview 2018.

OFFICE FOR TECHNOLOGY COMMERCIALIZATION UNIVERSITY OF MINNESOTA The Office for Technology Commercialization (OTC) facilitates the transfer of University of Minnesota research to licensees for development of new products and services that benefit the public good, foster economic growth and generate revenue to support the University’s research and education goals. www.research.umn.edu/techcomm

SILICON VALLEY BANK Silicon Valley Bank is the premier bank for technology, life science, cleantech, venture capital, private equity and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 27 U.S. offices and six international operations. (Nasdaq: SIVB)

S P O N S O R P RO F ILES

www.svb.com.

Established in 1999, and headquartered in Minneapolis, the Midwest Life Science team is responsible for a 10 state region that includes (IA, IL, IN, MI, MN, MO, ND, OH, SD and WI), as well as the Louisville KY area.

SQUARE 1 BANK Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion. Square 1’s expertise, focus and strong capital base provide flexible resources and unmatched support to meet our clients’ needs. The bank offers tailored products and solutions aided by the latest in technological innovations. Square 1 has offices coast to coast in Austin, Boston, Denver, Durham, Los Angeles, New York, San Diego, Seattle, Silicon Valley and Washington, DC. For more information, visit www.square1bank.com.

SWORD DIAGNOSTICS Sword Diagnostics is a leading-edge life sciences company created in response to the rapidly evolving needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today’s life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics’ technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays.

Sword’s mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

The Medical Research Organization NAMSA has provided services to medical device manufacturers for 45 years specializing in material safety testing and consulting for the majority of that time.

Through acquisition, NAMSA has added comprehensive regulatory and quality systems consulting, expanded functional studies with imaging capabilities, clinical research (including Field Clinical Engineers) and expanded educational services including physician and sales training.

Visit namsa.com to learn more about our services.

2012: The Integra Group joins NAMSA

2009: Alquest joins NAMSA 1993: Alquest is established with device-focused regulatory, clinical & quality services

2002: The Integra Group begins with combined preclinical, clinical & biostatistics

1967: NAMSA founded, providing comprehensive material safety testing

CVCA- CANADA’S VENTURE CAPITAL & PRIVATE EQUITY ASSOCIATION The CVCA - Canada’s Venture Capital & Private Equity Association was founded in 1974 and is the sole national representative of Canada’s venture capital and private equity industry. Its over 1900 members are firms and organizations which manage the majority of Canada’s pools of capital designated to be committed to venture capital and private equity investments. CVCA members’ collectively manage over $88 billion.

CVCA’s members actively collaborate to increase the flow of capital into the industry and expand the range of profitable investment opportunities. This is accomplished by the CVCA undertaking a wide variety of initiatives, ranging from developing comprehensive performance and valuation statistics, education and networking activities to promoting the industry’s interests with governments and regulatory agencies.

Join over 600 private capital professionals at the industry’s largest Canadian annual conference taking place in Banff Alberta from May 22-24, 2013.

S UP P O RT IN G O RG A N IZAT IO N

For more information, please contact: CVCA – Canada’s Venture Capital and Private Equity Association Tel: +1 416 487 0519 Fax: +1 416 487 5899 www.cvca.ca cvca@cvca.ca

DOW JONES - VENTURESOURCE Track VC-backed Companies & Their Investors Worldwide Dow Jones VentureSource is the venture industry’s most comprehensive, accurate and timely research database. It provides the highest quality data plus deep insights to support deal-sourcing, fund-raising, investment and partnerships.

• Browse profiles for some 90,000 VC-financed companies and investment firms worldwide • Search companies, investors and personnel by industry, round, region, keyword and more • Evaluate likely investments, deal opportunities or partnerships among VC-backed companies • Compare company valuations or measure performance for any sector, region or deal • See which VCs backed a company and the service providers involved in each financing • Follow developments with venture industry news from Dow Jones integrated into results and profiles • Spot emerging opportunities in all regions and industries, including niche sectors • Create attractive custom graphics or download reports in a number of convenient formats • Find and download contact details for key executives at companies and investment firms Data & Research You Can Rely On Dow Jones employs a time-tested methodology and multi-faceted approach to gathering, validating, and confirming private equity and venture capital data. We rely on a number of primary and secondary research sources, processes, and channels to source information.

Our global team of professional researchers works to not only verify information received, but also to collect the most complete, accurate details on venture capital-backed companies, investment firms and service providers.

For more information or to talk to a sales agent call Customer Service: 800-369-5663 or e-mail us ervice@dowjones.com

FREEMIND FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike.

FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

iBIO iBIO – the Illinois Biotechnology Industry Organization’s mission is to make Illinois and the surrounding Midwest one of the world’s top life sciences centers; a great place to do business and a great place to grow new technology ventures. With active support from corporate, academic and government leaders, iBIO promotes sound public policy at the local, state and federal levels; improves our region’s ability to create, attract and retain businesses; and orchestrates industry involvement to help solve America’s math and science education crisis.

ILPA The ILPA is the global, member-driven organization dedicated to advancing the interests of private equity Limited Partners through industry-leading education programs, independent research, best practices, networking opportunities and global collaborations.

MISSOURI VENTURE FORUM Missouri Venture Forum is a non-profit organization formed in 1985 that serves as a catalyst bringing together the people genuinely interested in helping entrepreneurs.

Missouri Venture Forum’s Mission is to serve entrepreneurs – those leading the growth of earlier stage businesses – through peer networking, topical education and access to capital resources.

Entrepreneurial activity and access to capital is facilitated through: • networking • education • information exchange Members include . . .

• Entrepreneurs • Private investors • Attorneys • Bankers • Venture capitalists • Accountants • Consultants • Educators • Marketing specialists • Corporate executives • Inventors MRUN MRUN members include commercialization and startup within universities and research institutions, early stage investors, entrepreneurs and service providers for startup companies. All MRUN members are within or interested in the Midwest. The MRUN community members work together to optimize and accelerate startup businesses by building relationships that support development and accelerate financing.

Expanded since the organizations founding in 2002, today the MRUN Region includes the states of Illinois, Indiana Iowa, Kansas, Kentucky, Ohio, Michigan, Minnesota, Missouri, Nebraska, North Dakota, South Dakota, Western Pennsylvania, and the Canadian provinces of Manitoba and Ontario. MRUN has three classes of members: full members, associate members and affiliate members.

MRUN has formed strategic alliances with organizations to establish an effective network for communications and collaborations to expand the network or outreach for companies and investors.

Some of these alliances include Burrill & Co., IBF, and others. www.mrun.us

S UP P O RT IN G O RG A N IZAT IO N

Initially founded as an informal networking group, the ILPA is a voluntary association funded by its members. The ILPA membership has grown to include over 270 member organizations from around the world representing over US $1 trillion of private assets globally.

Minnesota Warm-Up Reception December 4, 2012 | 5 - 7 p.m.

Minneapolis Convention Center

LIF ES CIEN CE A LLEY ®

Located in the LifeScience Alley Conference Exhibit Hall

MidAmerica Healthcare Venture Forum Guests Attend the Minnesota Warm-Up Reception Free of Charge

®

A DVOCATING

M AKING C ONNECTIONS

Do you know how state and federal policy are impacting you?

Do you need to connect with partners, suppliers, or other resources?

We’re an active voice on your behalf.

We perform 10,000+ referrals annually.

s m a n d l e @ l i f e s c i e n c e a l l e y. o r g

E DUCATING

e d u c a ti o n @ l i f e s c i e n c e a l l e y. o r g

B USINESS R ESOURCES

Do you have program and training ideas?

Do you need to save on operating costs or find talent?

We produce 100+ programs based on member input.

We offer critical discount programs and an active job board.

c o n n e c t @ l i f e s c i e n c e a l l e y. o r g

m e m b e r s h i p @ l i f e s c i e n c e a l l e y. o r g

Not a member? Contact membership@lifesciencealley.org.

MHIN is a nonprofit organization comprised of more than 30 venture capital firms, from every region of the country.

Our mission is to: • Encourage the syndication of financing for healthcare-related companies in Mid-America • Share expertise and experience among our member firms • Promote investing in Mid-American healthcare-related companies, nationally and globally • Help inform Congress on issues of importance to our members Founded in 2002, MHIN helps venture capital firms interested in Mid-America learn about investment opportunities and then syndicate the financing. Believing that you invest with people and firms you know and trust, we provide an opportunity for investors to get to know each other on a professional and personal basis.

MHIN also works closely with the National Venture Capital Association (NVCA) to represent our 30+ member firms.

Life science investment opportunities in the region include biotechnology, medical devices, bioinformatics, healthcare information technology, and healthcare services.

Fo r m o re i n fo r m at i o n v i s i t u s at : w w w. m h i n i n fo . c o m

M I D- A M E R I C A H EA LT H CA R E IN VES TO R NE T WOR K (M H IN )

Mid-America Healthcare Investors Network

COMPANY DESCRIPTION Abiogenix has created the uBox, a smart pillbox to help people take their medication on time. The uBox is the root of a powerful platform that allows for continuous and dynamic management of care. We include loved ones and clinicians in a person’s care circle in order to support and encourage them as they improve their medication adherence.

Targeting specialty pharmacy and controlled substances initially, we can help hospitals, insurers, and providers to avoid costly readmissions and other expenses associated with medication non-adherence. The uBox provides medication management in the palm of your hand.

P R ES EN T IN G CO M PA N IES

Sara Cinnamon President Abiogenix

BIOGRAPHY Sara is passionate about using her design experience help people, having previously worked on a non-invasive glucose meter and innovative mobility devices. She has her Master’s in Mechanical Engineering from MIT and B.S. from UC Berkeley. Sara has prior entrepreneurial product design experience and several patents pending for independent inventions.

COMPANY DESCRIPTION Advanced Circulatory has a novel therapy called Perfusion on Demand™- a therapy that has life saving implications for multiple emergency medical conditions with a total estimated global market opportunity of $3.3 Billion. Perfusion on Demand is a non-invasive therapy that increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised. This gives rescuers and caregivers the potential to return people to a full life after severe medical emergencies, including sudden cardiac arrest and traumatic brain injury.

Clinical research shows that Perfusion on Demand therapy improves survival with good neurologic function from sudden cardiac arrest, for example, by 53%. This equates to saving 50,000 lives a year.

Mike Black Chief Executive Officer Advanced Circulatory Systems, Inc.

BIOGRAPHY Mike Black serves as Chief Executive Officer and has been employed by Advanced Circulatory for 10 years, helping to evolve the company from a pre-revenue research and development organization to a break-even commercial operation with a $7 mm retail book of business. He previously held the positions of CFO and COO before being named CEO in 2008. Mr. Black has 15 years of experience with small companies including work in the areas of strategic planning, fund-raising, finance/accounting, marketing and operations. He also previously spent time at Deloitte & Touche as a financial auditor and consultant.

COMPANY DESCRIPTION AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms : prodrug development and microneedle formulations. AllTranz ‘s products targeting large and growing markets to treat pain, osteoarthritis, cancer chemotherapy nausea and vomiting, alcoholism, and decreased appetite in AIDS and cancer patients, as well as an abuse deterrent treatment for opiate addiction. AllTranz will have its first product through Phase I trials in 2013 and a second product entering the clinic six months later. AllTranz recently completed a first close for its Series B financing.

BIOGRAPHY George Emont is the Chairman and Acting President of AllTranz, Inc. Mr. Emont is also a managing partner with Triathlon Medical Ventures and the Kentucky Seed Capital Fund.

Mr. Emont’s more than twenty five years of health care industry experience include 17 years in venture capital.

Mr. Emont was Director of Venture Capital for Humana Inc. where he managed a venture capital fund that made investments totaling over $75 million in 11 portfolio companies and three venture funds.

Earlier, Mr. Emont’s worked at Baxter Healthcare Corporation, IAI Venture Capital Group, followed by the successful launch and sale of OncoTherapeutics.

COMPANY DESCRIPTION Altheus Therapeutics, Inc. is developing Zoenasa® Oral Controlled Release and Rectal Gel formulations as novel front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus a powerful antioxidant and anti-inflammatory agent to reduce bowel injury associated with IBD. Altheus has initiated a Phase 2 clinical trial to establish the efficacy of Zoenasa Rectal Gel in patients with leftsided UC(ZA-201). Altheus is raising Series B to complete ZA-201, development for Zoenasa Oral products, and supportive corporate activities.

Dennis Schafer President & CEO Altheus Therapeutics, Inc.

BIOGRAPHY Dennis Schafer is an accomplished entrepreneur with 25 years’ experience in organizing and managing new life science ventures. He has played leadership roles in ten start-ups, serving as CEO in several, accessing technologies from various universities; raising start-up capital from institutional venture funds; and forming corporate partnerships with major and mid-major pharmaceutical companies. Companies in his portfolio include BioCryst Pharmaceuticals, Zynaxis (acquired Secretech), Avant Immunotherapeutics (acquired Megan Health), Coley Pharmaceuticals, Aderis Pharmaceuticals, Somatacor, and Altheus Therapeutics. Mr. Schafer received his BA with distinction from the University of Nebraska, an MA in English and an MBA from the University of Virginia.

P R ES EN T IN G CO M PA N IES

George Emont Chairman and Acting President AllTranz, Inc.

COMPANY DESCRIPTION ALung has developed the Hemolung™, an extracorporeal artificial lung that will replace or supplement the ventilator in the ICU for acute respiratory failure. The Hemolung will provide 50% of a patient’s respiratory need, allowing the lungs to heal, eliminating the need for intubation, sedation and mechanical ventilation.

The Hemolung™ will reduce the incidence of ventilator associated pneumonia and hospital length of stay, resulting in a reduced cost of care for these patients. The Company has completed animal and human trials.

Outcomes data is very positive with no device related adverse events and the Company will initiate commercialization in Europe in Q1 2013.

P R ES EN T IN G CO M PA N IES

Pete DeComo CEO ALung Technologies, Inc.

BIOGRAPHY Pete DeComo is CEO of Alung, the developer of an artificial lung for patients with Respiratory failure. Prior, he was founder and CEO of Renal Solutions where he developed a dialysis technology for patients with kidney failure. There he raised $40M in equity financing, completed the development process and in November 2007 Renal was acquired for $200M, significant considering Renal was pre-revenue.

Mr. DeComo is the recipient of many awards including the following; • E&Y “Entrepreneur of the Year” for 2008 • Pittsburgh Venture Capital Association “Entrepreneur of the Year” for 2008 • Carnegie Science Center “Entrepreneur of the Year” in 2005

COMPANY DESCRIPTION Ativa is an emerging growth company that is developing and will commercialize unique solutions for streamlining the diagnostic process in smaller primary care settings globally. Ativa’s solution is designed to streamline the primary care diagnostic process, reduce cost and improve patient care. Our platform will expand access to modern diagnostic testing for an estimated 2+ billion people around the world that presently do not have access. Our platform consists of a powerful, compact, affordable blood analysis system and companion diagnostic decision support software that can easily integrate third party biometric and vital sign data to provide physicians with a comprehensive patient workup prior to seeing the patient.

David Deetz CEO & President Atvia Medical

BIOGRAPHY Mr. Deetz is is the founder and CEO of Atvia Medical, a development stage diagnostic technology business.

Mr. Deetz also started PPG Biomedical and Diametrics Medical, one of which completed a successful IPO, and both of which were acquired by industry leaders and still operate today.

COMPANY DESCRIPTION CardioInsight Technologies (CIT) is commercializing a non-invasive, advanced cardiac mapping technology that generates real-time, 3D maps of the electrical activity of the heart, in a single beat. CIT¹s CE Marked ECVUETM system provides electrophysiologists with a powerful, yet simple, non-invasive solution to address two large, high-growth market opportunities; 1) mapping of complex cardiac arrhythmias, including atrial fibrillation (AF), and 2) optimization of cardiac resynchronization therapy(CRT) for heart failure. Moreover, ECVUE is the only system able to extend advanced cardiac mapping outside the confines of the EP lab, expanding the utility of advanced mapping and improving the cost effectiveness of EP procedures.

BIOGRAPHY Before joining CardioInsight Technologies, Inc., Mr. Wethington served as CEO at Hemosphere, Inc., a leading medical device company focused on cardiac and vascular surgery that was acquired by Cryolife in May 2012.

Mr. Wethington served as global Vice President of sales and marketing at Gambro Inc., formerly CHF Solutions, where he oversaw the successful commercialization of CHF¹s Aquapheresis Peripheral Ultrafiltration System.

Prior to Gambro, Mr. Wethington spent 10 years in various sales and marketing leadership positions at St. Jude Medical Endocardial Solutions, Inc. Mr. Wethington started his career with CPI Guidant, now part of Boston Scientific, where he held numerous clinical, product development and brand management roles. He has a Bachelor of Arts degree from Clemson University and a Masters of Business Administration from the Carlson School of Management at the University of Minnesota.

COMPANY DESCRIPTION Cell Habitats, Inc. is redefining the field of tissue repair by using biological and physical cues to prompt the body’s own stem cells to restore normal function to damaged or diseased tissue. CH’s novel approach is accomplished by injecting Regenerods, micro-sized devices that mimic biological material, attract the body’s own stem cells, and act as a substitute cellular habitat that promotes endogenous stem cell growth. This innovation could potentially improve outcomes in the treatment of heart muscle disease and serves as a platform for repair of bone, cartilage, muscle and nerve tissues. Cell Habitats is a Flavin Ventures portfolio company.

John L. Flavin, MBA CEO Cell Habitats, Inc.

BIOGRAPHY John is Managing Director of Flavin Ventures, LLC and CEO of Cell Habitats. With over 20 years of experience in the life sciences field, he has led two successful NASDAQ IPOs, and raised over $220 million in funding.

John was co-founder, President, CFO and board member for Advanced Life Sciences for 10 years. John was also instrumental in building MediChem Life Sciences, a drug discovery and development company. Mr. Flavin is a member of the life sciences diligence panel for the Invest Illinois Venture Fund. John holds a B.S. in Business Administration from Marquette University and M.B.A. from Lewis University.

P R ES EN T IN G CO M PA N IES

Pat Wethington President & CEO CardioInsight Technologies, Inc.

COMPANY DESCRIPTION Delphinus Medical Technologies has succeeded in building a three-dimensional full-breast ultrasound imaging device that effectively differentiates benign from malignant masses in breast cancer cases using a safe (non-ionizing), comfortable (non-compressing), and reliable patented technology (“SoftVue”). The SoftVue system is targeted at the rapidly growing diagnostic portion of the market to address risk assessment and chemotherapy follow-up followed by entry into the screening market. The To-date Delphinus has raised $12M in financing, which has allowed it to develop the SoftVue system and complete its first 510(k) filing. The company is seeking to raise $17M to commercialize the system and develop adjunct products.

P R ES EN T IN G CO M PA N IES

William C. Greenway Chief Executive Officer Delphinus Medical Technologies

BIOGRAPHY Over 26 years experience in the medical imaging industry. Former CEO of Infimed and Lodox Systems Former VP of Business Development of Hologic Held a variety of engineering and manufacturing positions at GE.

COMPANY DESCRIPTION Founded in September 2008, Diagnostic Photonics is developing advanced imaging technology to assist clinicians in the evaluation of the presence and extent of cancer during surgery. The company’s Enlighten imaging probe and system place a live view of tissue microstructure at the surgeon’s fingertips, providing immediate insight into cancer pathology during surgery. With knowledge of tissue microstructure in hand, clinicians can make more informed decisions and provide better care. The company’s breakthrough intraoperative imaging technology originated in the Beckman Institute for Advanced Science and Technology at the University of Illinois, and the company is funded by IllinoisVentures and Serra Ventures.

Andrew Cittadine CEO Diagnostic Photonics

BIOGRAPHY Andrew has 15 years of leadership experience as a cofounder or chief executive in four medical device companies. He co-founded and served as CEO of medical device startup American BioOptics (acquired), served as the interim CEO for venture-backed startup SonarMed, and co-founded Sensant Corporation, a Silicon Valley-based, 3D medical imaging firm that was acquired by Siemens.

Andrew received a BA in History and a BS and MS in Electrical Engineering from Stanford University where he was elected to Tau Beta Pi. He holds an MBA with distinction from the Kellogg School of Management at Northwestern University.

COMPANY DESCRIPTION Flow Forward Medical, LLC (“Flow Forward”) is developing the Arteriovenous Fistula Eligibility (AFE) System™, a cardiovascular medical device for improving eligibility and reducing maturation failure of arteriovenous fistula (AVF) vascular access sites for hemodialysis. The AFE System is a small, wearable, temporary, minimally-invasive rotary blood pump system designed to rapidly and persistently dilate veins prior to AVF surgery. Flow Forward was founded in August 2010 as a subsidiary of Novita Therapeutics, LLC, a privately held medical device incubator | accelerator that has raised $7 million to develop new products and spin out independent companies backed by venture financing.

BIOGRAPHY F. Nicholas Franano, MD is founder and CEO of Flow Forward Medical and its parent company Novita Therapeutics. Dr. Franano previously founded Proteon Therapeutics (“Proteon”) and served as CEO from 2001 - 2006 and Chief Scientific Officer from 2006 - 2009, inventing key technologies and helping raise $74M. In 2009, Proteon was named a Fierce Biotech Top 15 company and was selected as a 2010 Technology Pioneer by the World Economic Forum. Dr. Franano currently serves as a member of the Proteon Board of Directors.

He trained at Johns Hopkins Hospital and practiced as an interventional radiologist from 2000 – 2006.

COMPANY DESCRIPTION FluGen Inc. is leading the fight to dramatically improve the effectiveness of influenza vaccines. This leadership in the $4 billion flu market is driven by the first real universal flu vaccine candidate (REDEE FLU™) and its novel intradermal delivery technology which makes existing vaccines far more effective. The Company will be in the clinic in early 2013. FluGen has raised over $10 million to date and is seeking an additional $10 million to move its REDEE FLU™ vaccine through Phase II clinical trials, and to further develop its microneedle device for large scale manufacturing and multiple vaccine delivery.

Paul V. Radspinner President & CEO FluGen Inc.

BIOGRAPHY Mr. Radspinner President and CEO of FluGen Inc., a Madison, Wisconsin influenza vaccine and vaccine delivery company where he has raised over $10 million. He has broad experience including multiple US and international management roles at Eli Lilly & Company and the Wisconsin Alumni Research Foundation (WARF) and Deltanoid Pharmaceuticals where he was VP of Business Development. In 2011 Mr. Radspinner was appointed

by Wisconsin Governor Walker to the Wisconsin Economic Development Corporation (WEDC) board of directors where he now serves. He is also a board member of the biotechnology association, BioForward.

P R ES EN T IN G CO M PA N IES

F. Nicholas Franano, MD Founder and CEO Flow Forward Medical, LLC

COMPANY DESCRIPTION Healthsense, the fastest growing provider of aging services technology, provides technology-enabled care solutions for the entire senior care continuum. With a full range of remote monitoring, emergency response, and wellness management solutions, Healthsense helps senior care providers reduce costs, increase independence, and enhance caregiver and senior experiences. Built on a Wi-Fi platform, Healthsense products are scalable and enable flexible technology-enabled care designs that help communities deliver the highest quality of care.

P R ES EN T IN G CO M PA N IES

Brian J. Bischoff Co-founder, President & CEO Healthsense, Inc.

BIOGRAPHY Brian J. Bischoff, Co-founder, President & CEO of Healthsense, Inc. is an acknowledged leader in the field of product development and application of sensing and control technology. He has had the privilege of being the principal investigator on three National Institute of Health (NIH) and two Defense Advanced Research Projects Agency (DARPA) grants directed at technology enabled care.

He has been developing and commercializing new products for 24 years and holds twelve patents. His career has included key leadership positions with Emerson Process Management and Honeywell, where he was selected as one of thirty-three global executives to participate in the Vision 2005+ project to define strategic trends that would shape the company and society over a five- to ten-year horizon.

Following the Vision 2005+ project, he managed the large, global, Control Products business unit for Honeywell, making significant operational improvements.

Brian holds Bachelor of Science and Master of Science degrees in Mechanical Engineering from the University of Minnesota.

COMPANY DESCRIPTION HistoSonics completed development of the Vortx RX® for treatment of Benign Prostatic Hyperplasia (BPH).

The Vortx RX combines focused ultrasound Histotripsy and ultrasound imaging for non-invasive, image guided tissue ablation. Histotripsy is non-thermal and ablates tissue mechanically with highly energetic cavitation “bubble clouds”. Pre-clinical verification in canines showed that Histotripsy ablation resulted in minimal inflammation and rapid healing. HistoSonics recently submitted an IDE to the FDA and plans to initiate pilot clinical studies in early 2013. HistoSonics completed an $11 million Series A financing in late 2009 and is planning a $12 million Series B financing mid 2013.

Tom Davison, PhD. Chairman, CEO & Co-Founder HistoSonics, Inc.

BIOGRAPHY Tom Davison, PhD. is Chairman, CEO and co-founder of HistoSonics, Inc. Prior to HistoSonics, Dr. Davison was CEO of Sontra Medical which merged with Echo Therapeutics; he was founder and CEO of Endius which was acquired by Zimmer, and founder and President of UltraCision (Harmonic Scalpel) which was acquired by Johnson and Johnson. Dr. Davison has served on the boards of 11 public and private companies. He holds over 30 patents on medical device technologies and products including, the Harmonic Scalpel and Endius minimally invasive spine fusion system. Dr. Davison earned his PhD. in Mammalian Physiology from Kent State University.

COMPANY DESCRIPTION Imricor produces the devices needed to perform atrial fibrillation and other ablation procedures in an MRI, rather than in an X-ray lab. Imricor’s MRI based procedures allow doctors to see the heart in real time while they work, so they can more accurately target ablation sites and visually assess ablation lesion quality. MRI guided procedures are radiation free, so they are safer for both the patient and the doctor.

Imricor’s products are uniquely MRI compatible. Conventional ablation devices cannot be used with MRI. Imricor has completed its first in man pilot study and is engaged in further clinical development studies.

BIOGRAPHY Steve Wedan has a BS in Electrical Engineering from Michigan Technological University, summa cum laude, and an MS in Electrical Engineering from Marquette University. He has over 20 years of medical device experience, including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Prior to co-founding Imricor, Mr. Wedan founded and operated a successful consulting company, Wedan Technologies Inc., from 2000-2006. Mr. Wedan is a U.S. appointed expert in the fields of MRI safety and the compatibility of implanted and interventional products in MRI.

COMPANY DESCRIPTION IntelliCyt develops, manufactures, and markets proprietary cell-based screening solutions consisting of instrumentation, informatics software, and assay kits used to improve sensitivity of lab tests, increase throughput, simplify workflow and reduce costs. Cell-based tests have emerged as an important field of research as new technologies have made it possible to measure cellular differences in living organisms and correlate the variation with changes in biological function and disease processes. IntelliCyt’s solutions enable their customers to understand what makes individual cells unique and to pave the way for medical treatments that are based on disease mechanisms at the cellular level..

R. Terry Dunlay CEO IntelliCyt

BIOGRAPHY R. Terry Dunlay, CEO – Terry is an experienced entrepreneur with over 20 years of experience in life science technology development and commercialization. Previously, he was co-founder and Executive Vice President of Cellomics, where he invented and commercialized the company’s high content screening instrumentation and informatics. Prior to Cellomics, Terry was founder and CEO of Biological Detection, Inc. and Vice President of Biological Detection Systems, Inc. and was in product development at Cytyc Corporation. He holds 15 patents in the area of cell-based screening instrumentation and informatics.

P R ES EN T IN G CO M PA N IES

Steve Wedan CEO Imricor

COMPANY DESCRIPTION Intuitive Biosciences is a MDx company initially focused on serving the food production and pharmaceutical research industries. Intuitive has three products in the market and a robust product development pipeline.

The $160 million dollar research animal testing market gives Intuitive a rapid path to profitability and builds a base for expanding into the $700 million dollar cattle production market. Intuitive has established customers in the research animal market, including over one-third of the U.S. National Primate Centers and multiple CRO commercial partner

P R ES EN T IN G CO M PA N IES

Shawn Guse CEO Intuitive Biosciences

BIOGRAPHY Shawn Guse, CEO. Led several successful technology companies, including: CEO, Compact Particle Acceleration Corporation; VP-International Operations and General Counsel, TomoTherapy. He is also Chairman, Echometrix and Director, Apartia Pharmaceuticals.

COMPANY DESCRIPTION Metactive Medical™, LLC (“Metactive”) is developing novel, catheter-based cardiovascular medical devices.

Metactive’s Ballstent Microcatheter™ is designed to completely fill and seal cerebral aneurysms with one simple device deployment, offering an easier, faster, and more durable repair at a reduced overall cost. Metactive is also developing the Blockstent Microcatheter™ to provide rapid and complete occlusion of peripheral arteries.

Metactive was founded in August 2011 as a subsidiary of Novita Therapeutics, LLC, a privately held medical device incubator | accelerator that has raised $7 million to develop new products and spin out independent companies backed by venture financing.

Xandra M. Sifuentes President Metactive Medical, LLC

BIOGRAPHY Xandra M. Sifuentes, MBA is the President of Metactive Medical. She previously founded two medical device start-up companies, invented medical devices through the University of Missouri’s Biodesign and Innovation Program, and developed business plans for high-growth technology ventures at the Missouri Innovation Center.

She also has several years of engineering experience from Honeywell International and Garmin International.

Ms. Sifuentes is currently a regional innovator in PIPELINE, the nation’s premier technology entrepreneur immersion program.

COMPANY DESCRIPTION Monteris® Medical Corporation is a privately held medical device company dedicated to the development of minimally invasive, MRI-guided neurosurgical solutions. We strive to provide options for surgeons treating brain cancer. The NeuroBlate™ System is a laser-based ablation system for intracranial lesions, including brain tumors.

The AXiiiS® Stereotactic Miniframe is a single use platform for image guided device delivery and brain biopsy.

The AtamA™ Head Coil and Stabilization System facilitates intra-operative imaging and neurosurgical access for MRI-guided procedures requiring head fixation. Monteris Medical: “A Ray of Light….A Ray of Hope” www. monteris.com

BIOGRAPHY John Schellhorn is currently President & CEO of Monteris Medical. Previously, Schellhorn was Chief Commercialization Officer for BÂRRX Medical (BÂRRX was acquired by Covidien in January 2012). Schellhorn also served as President & CEO of Softscope Medical Technologies Inc., a venture backed G.I. company sold to FUJIFILM Corp. in 2010. He was also VP of Sales & Marketing, Peripheral Vascular Division of ev3 Inc., VP & General Mgr. International, ACMI Corporation, (acquired by Gyrus PLC in 2005), along with management positions at Boston Scientific. Schellhorn graduated Summa Cum Laude from Long Island University and served 7 years as a U.S. Marine Corps pilot.

COMPANY DESCRIPTION NxThera’s Rezūm™ endourology technology platform is designed to transform the experience of urologists and their patients in the treatment of benign prostatic hyperplasia (BPH), prostate cancer and kidney cancer. The Rezūm system treats prostate tissue in a matter of seconds, delivering targeted thermal energy in the form of sterile water vapor without the need for patient anesthesia. Developed first as an office-based procedure for treating BPH, data from pilot clinical studies are compelling. The Company expects to begin its pivotal study, receive CE mark and continue development of the prostate cancer application of the Rezūm technology platform in 2013.

J. Robert Paulson, Jr. President & CEO NxThera’s Rezum™

BIOGRAPHY Bob Paulson is the President & CEO, and a director at NxThera. With more than 20 years of experience in the medical device industry, Bob previously was President, CEO and a director of Restore Medical until the company’s acquisition by Medtronic in 2008. Prior to Restore, Bob was the CFO and VP Global Marketing for Endocardial Solutions, which was acquired by St. Jude Medical in 2005. Previously, Bob held executive positions with Medtronic and Advanced Bionics. Bob received his J.D., Vanderbilt University School of Law; M.B.A., University of St. Thomas; and B.A. in accounting, economics & political science, Luther College.

P R ES EN T IN G CO M PA N IES

John Schellhorn President & CEO Monteris Medical

COMPANY DESCRIPTION Preceptis Medical, Inc. is a device manufacturer developing tools and anesthetic regimens to allow tympanostomy procedures (ear tubes) to be performed outside of the operating room, eliminating the risk of general anesthesia and significantly reducing costs to the healthcare system. Preceptis has completed human proof of concept on less than $1M in less than 11 months.

The worldwide market for tympanostomy procedures is over $1B annually; the Preceptis device is exempt from 510(k) clearance; reimbursement is already in place; and the Preceptis solution improves outcomes for all stakeholders. Preceptis Medical can be viewed as the poster child for healthcare reform.

P R ES EN T IN G CO M PA N IES

Steven Anderson CEO Preceptis Medical, Inc.

BIOGRAPHY Steve Anderson is the CEO of Preceptis Medical, Inc, a medical device ENT start-up developing tools and anesthetic regimens which allow pediatric tympanostomy surgery to be performed without the risk of general anesthesia or the costs associated with an OR. Prior to this position, he was the President of Acorn Cardiovascular, Inc., a medical device manufacturer developing life-sustaining therapies for the treatment of systolic heart failure. Mr. Anderson has 30 years of experience in the medical device industry, starting with Medtronic and including senior management positions at St. Jude Medical, TĂœV Product Service, St. Croix Medical, and Acorn Cardiovascular. His specific core competencies include development, regulatory, clinical, reimbursement, quality, and compliance.

Mr. Anderson has a BS in Materials Engineering and an MS in Biomedical Engineering from the University of Minnesota. He was an Adjunct Professor at the University of St. Thomas Graduate School, has served on multiple boards for medical device companies (both public and private), and has authored numerous publications on medical device regulation and reimbursement (both US and worldwide).

COMPANY DESCRIPTION Pulse Therapeutics developed a novel medical device designed to significantly increase the effectiveness of the clot-busting drug tPA for the emergency department based treatment of ischemic stroke. Pulse demonstrated in pre-clinical studies that intravenously-administered biocompatible iron particles, when controlled by a compact external magnet, substantially accelerate the diffusion of chemical agents, without the need to attach the drug to the magnetic particles. The Company believes that its proprietary technology will allow tPA to reach the clot more quickly and at higher concentrations, resulting in dramatically faster dissolution of the clot as compared to standard IV-tPA delivery.

James C. Wachtman CEO Pulse Therapeutics

BIOGRAPHY James C. Wachtman currently serves as CEO of Pulse Therapeutics, a development stage medical device company focused on treating ischemic stroke. He is a Venture Partner for SV Life Sciences (Healthcare Services sector) since 2009. Jim served from 2004 to 2009 as President and CEO and a member of the Board of Directors of TLC Vision, Inc. (NASDAQ:TLCVF), a national provider of eye care services. Jim began his 29 year healthcare career in sales at American Hospital Supply (McGaw Division), rising to Vice President, infusion device sales before becoming one of the founding executives of Central Admixture Pharmacy Services.

COMPANY DESCRIPTION Test at home, treat online...that’s QuickCheck Health, the “retail clinic in a box”. QuickCheck Health’s goal is to bring affordable health care to people, even in remote locations, developing rapid over-the-counter home diagnostic tests for common illnesses such as strep throat, urinary tract infection and many others. QuickCheck Health will bring benefits to consumers through lower cost, high quality care, physicians by freeing up time for more complex cases and large groups, such as employers, insurers and government agencies, by reducing the cost of treating routine illnesses by as much as 75% or more

BIOGRAPHY Mr. Henke has over 25 years of health plan experience including leadership positions at Medica, Allina, EBP HealthPlans and Prudential Health Care. His most recent plan experience included Chief Innovation Officer as well as Senior Vice President & General Manager for Medica’s commercial markets division representing 1.3 million members and $3.5 billion of premium or premium equivalent.

A co-founder of QuickCheck Health, he is a frequent speaker regarding both disruptive innovation in health care and empowering consumers.

Mr. Henke has a masters in business administration (finance) from the University of St. Thomas.

COMPANY DESCRIPTION Respira Therapeutics, Inc. is an inhaled pharmaceutical product development company focused on applying its breakthrough high efficiency dry powder inhaler (DPI) delivery technology as a competitive weapon to deliver a pipeline of differentiated mono and combination therapy inhaler/drug products to address major inhaled medication market needs and opportunities. Respira’s proprietary DPI position and superior delivery performance will allow Respira’s branding of off patent drugs and also delivery of NCEs not currently possible by current DPI technologies. Respira’s lead pipeline product is a risk reduced, multidose inhaler / combination therapy drug product for the chronic treatment of asthma and COPD. Bob Curtis President & CEO Respira Therapeutics, Inc.

BIOGRAPHY Bob is President & CEO of Respira Therapeutics, Inc. He has an extensive background in the medical technology field in a 30+year career as a technologist, senior executive, founder and operating manager of multiple life science technology startups, and as a venture capital accelerator/incubator manager and investor.

Bob has raised and invested over $190 million in corporate and venture capital and has managed technology-driven companies in multiple medical specialty markets ranging from seed-stage venture backed start-ups to subsidiaries of large multinational health care corporations. He was an early-stage CEO at Aerogen, Inc. (NASDAQ: AEGN), a metered dose inhaler company.

P R ES EN T IN G CO M PA N IES

Tom L. Henke President & CEO QuickCheck Health

COMPANY DESCRIPTION Securus has developed the L-ViewTM Thermal Monitoring System which provides the clinician with a non-contact, high resolution, thermographic map of tissue temperature thereby improving both the safety and efficacy of ablation therapy. The initial application of the technology will focus on esophageal temperature mapping for the rapidly growing >$1B cardiac ablation market. An abstract summarizing animal studies was presented at the American Heart Association in November 2012. The Company raised $2.6M Series A and is seeking investors for a $6.5M Series B financing which will allow completion of commercial product development, 510(k) submission and approval by late 2014.

P R ES EN T IN G CO M PA N IES

Donna Richardson President & CEO Securus Medical Group, Inc.

BIOGRAPHY Donna Richardson, President & CEO, has more than 30 years experience in the medical device sector leading three previous start-up companies. She has extensive expertise in strategic planning, product development, sales & marketing, clinical trials, market assessments, fundraising and all aspects of early stage healthcare companies. She recently served as Entrepreneur-in-Residence for JumpStart, Inc., and has worked closely with BioEnterprise in Cleveland. She is a Registered Nurse & earned a Master’s Degree, Business Policy, Columbia University.

COMPANY DESCRIPTION Pharmaceutical companies are under intense pressure to discover and market new drugs. Drug-target protein maps are crucial for the design and development of potent and specific drugs. By utilizing innovative technology, Shamrock Structures helps companies rapidly obtain these drug-target protein maps. Shamrock is a drug discovery services company that provides pharmaceutical researchers with access to technologies and expertise in protein crystallography, medicinal chemistry and biological screening to help discover more lead compounds for its pharma customers.

Michael T. Flavin, Ph.D. CEO Shamrock Structures

BIOGRAPHY Dr. Flavin is Managing Director of Flavin Ventures, LLC and CEO of Shamrock Structures. Prior to joining Shamrock, Michael was CEO of Advanced Life Sciences where he led the company’s IPO. Prior to Advanced Life Sciences, Dr. Flavin founded and built MediChem Life Sciences as a premier drug discovery and development company focused on chemistry and biology. Dr. Flavin has 45 publications in scientific journals and 20 U.S. Patents in the fields of organic chemistry, medicinal chemistry and biochemistry. Michael received his B.S. degree in chemistry from Notre Dame and his Ph.D. degree in medicinal chemistry from University of Illinois at Chicago.

COMPANY DESCRIPTION Siloam Biosciences, Inc. (founded 2004) is focused on developing the next generation In-Vitro Diagnostic (IVD) systems based on its proprietary microfluidic technology. The company has already commercialized the Optimiser™ microfluidic ELISA microplate as the platform technology with significant performance benefits, most important being low sample volumes (20x lower than current), very high sensitivity (100x better), and rapid test times (30 min as opposed to 4-6 hours). Siloam has demonstrated proof-of-principle that Optimiser™ technology can also be adapted for point-of-care test (POCT) applications making it the only seamless IVD platform to span multiple test settings.

BIOGRAPHY Aniruddha Puntambekar, PhD (Chief Operating Officer); Dr. Puntambekar is the lead inventor for the revolutionary Optimiser™ microplate system and has over 14 years of experience in microfluidic system development. He has managed the development of the paradigm shifting approach in developing the novel Optimiser™ microplate technology and extending its application beyond a lifescience consumable to an IVD/ POCT system component. In addition to the strategic growth objective charter, he is also responsible for operations management at Siloam. Dr. Puntambekar also serves on the Industrial Advisory Board for Ohio Center of Microfluidic Innovation at the University of Cincinnati.

COMPANY DESCRIPTION SironRX Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies to accelerate wound repair and prevent scarring of dermal wounds. The company is currently enrolling patients in a placebo-controlled, randomized double-blinded clinical study evaluating the safety and efficacy of its lead product, JVS-100. This product is a clinically tested DNA plasmid based therapy that induces the production of Stromal cell-Derived Factor 1 (SDF-1), a chemokine important in the body’s natural tissue repair process. Company investors include North Coast Angel Fund, Fletcher-Spaght Ventures, Glengary LLC, Ohio Tech Angel Fund, Early Stage Partners, the Cleveland Clinic and JumpStart.

Evan A. Facher, Ph.D. President & CEO SironRX Therapeutics, Inc.

BIOGRAPHY Evan A. Facher, Ph.D. is the President & CEO of SironRX. He came to SironRX after spending approximately 8 years at MEDRAD, part of Bayer AG’s Medical Device organization. During his time at Bayer/MEDRAD, Dr. Facher was involved with leading business development, corporate strategy, M&A and product development. His most recent appointment there was as General Manager of Bayer’s global cardiovascular fluid delivery business.

Prior to Bayer, Dr. Facher worked at Athersys, Inc., where he was focused on business development, strategy and fundraising. Dr. Facher holds an MBA from Case Western Reserve’s Weatherhead School of Management, a Ph.D. in Human Genetics from the University of Pittsburgh and a B.S. in Biology from the University of Miami.

P R ES EN T IN G CO M PA N IES

Aniruddha Puntambekar, Ph.D. Chief Operating Officer Siloam Biosciences, Inc.

COMPANY DESCRIPTION Ubiqi Health is a mobile-enabled personal discovery platform that serves the millions with chronic conditions.

By combining an engaging data-gathering framework manifested through mobile apps and a sophisticated data aggregation engine, we empower people to do their own investigations to identify which treatments or lifestyle changes positively impact their health. Through the data amassed through our users, the Ubiqi Health platform also creates a store of clinical evidence that is leveraged by healthcare organizations to ensure that people are getting the most appropriate treatment for their individual needs.

P R ES EN T IN G CO M PA N IES

Anshuman Sharma Chief Technology Officer Ubiqi Health

BIOGRAPHY Anshuman Sharma has over 10 years of experience in system design encompassing hardware, firmware and application software. He started his career at Medtronic developing class III medical devices and systems for drug delivery and neuro-stimulation and then held leadership roles in R&D, program management and process-driven engineering across an array of small and large medical device companies. Prior to founding Ubiqi Health, Anshuman was VP of Engineering at an early-stage startup based in the San Francisco Bay Area. He holds an MS in Electrical Engineering from University of California at Berkeley and a BS in Electrical and Computer Engineering from Georgia Institute of Technology.

COMPANY DESCRIPTION Zipnosis provides online diagnosis and treatment of common health conditions. Our powerful digital diagnosis platform is offered directly to consumers and employers to achieve dramatic cost and time-savings over a clinic visit. We also license the technology to partners in a Powered by Zipnosis format, allowing them to reap the same benefits. During an 18 month pilot in Minnesota, Zipnosis has treated over 10,000 patients. By using Zipnosis, those patients have saved over $1.5M and employers have gained back nearly 15,000 hours of productivity. Service will be live in 7 more states starting January 1, 2012.

Jon Pearce Co-founder & CEO Zipnosis

BIOGRAPHY Jon Pearce is the Co-founder and CEO of Zipnosis. Prior to starting Zipnosis, Jon worked as a product manager for ProVation Medical, a successful healthcare IT start-up that was acquired by Wolters Kluwer in 2006. In 2008, Jon won the MN Cup with the Zipnosis business plan while attending Carlson School of Management for his MBA. He has a B.A. in Russian Language from St. Olaf College and is often found running, biking and swimming around the Twin Cities.

International Business Forum is a business research group and a full-service conference production company with a focus on technology innovation and venture capital investing.

Founded in 1989, International Business Forum has been organizing conferences that provide attendees with strategic information, key business contacts and the opportunity to gain access into the highest level of business intelligence from global industry leaders.

IBF’s ability to facilitate strategic gatherings has resulted in countless business relationships and transactions over the years. Our commitment to producing quality over quantity is what continues to distinguish IBF. Our current line-up of events includes: •

Corporate Venturing & Innovation Partnering Conference

•

Consumer Health & Wellness Innovation Summit

•

Digital Healthcare Innovation Summit

•

Medtech Investing Conference

•

ORX Orphan Drug Summit

•

Innovation AwardsTM

•

Venture Capital Investing Conference

•

Ophthalmology Innovation Summit

•

Institutional Limited Partner Association GP Summit

•

MidAmerica Healthcare Venture Forum

•

ENT Innovation Summit

•

Healthcare Growth Equity Summit

TESTIMONIALS

“

“Congrats again for putting together such a great production. The speakers, the content, the attendees, all world class. IBF does it again!

Well done.”

- Stephane Dupont UBS Global Asset Management

“

“Hats off to the IBF for putting together an impressive first outing for the Consumer Health & Wellness Innovation Summit.

The program was as diverse as this area of endeavor with something for everyone in attendance.”

- Heather Ready Vice President of Marketing Mobile AcuFocus

STAY CONNECTED!

Linkedin Twitter Facebook

FOR MORE INFORMATION CONTACT:

“

“I was very impressed with the quality of the speakers and thoroughness of organization.

I appreciate the recruitment of speakers from great background and deep experience, as this made the discussion and presentation relevant.”

- Chris Haase Business Advisor to CTO Shell International Exploration & Production Inc.

“

“IBF is an industry leader, great partner, and distinguished forum for all investors. Their conferences offer an excellent mix of quality attendees and industry updates. IBF helped unite numerous contacts which have resulted in long term relationships.”

- Baiju Shah President & CEO Bio Enterprise

w w w. i b f c o n f e r e n c e s . c o m

ALEXANDRA SCOTT CEO Alex@ibfconferences.com CHRISTINA RIBOLDI PRESIDENT Christina@ibfconferences.com CRAIG SIMAK CHIEF STRATEGIC OFFICER Craig@ibfconferences.com DANIELLE PAPPAS EXECUTIVE PRODUCER Danielle@ibfconferences.com MELANIE SERGE PROJECT DIRECTOR Melanie@ibfconferences.com

A GE N D A AT - A - G L A N CE DECEMBER 4, 2012 7:00 – 7:40 am

Continental Breakfast and Conference Registration

7:40 – 7:50 am

Welcome and Opening Remarks

7:50 – 8:10 am

Industry Update

8:10 – 8:30 am

Advancing Commercialization at the University of Minnesota

8:30 – 9:15 am

Mobile Technology Disrupting the Traditional Healthcare Business Models

9:15 – 10:00 am

Views From Serial Entrepreneurs: The Landscape Today vs. 5-10 Years Ago

10:00 – 10:30 am

Networking and Refreshment Break

10:30 – 11:15 am

Healthcare Investment Trend: Shift from Medical to Industrial

11:15 – 12:30 pm

Company Showcase Medical Devices

Biopharmaceuticals/Regenerative Medicine Diagnostics/Tools

12:30 – 1:20 pm

Luncheon

1:20 – 2:30 pm

2:30 – 3:15 pm

Company Showcase Medical Devices HealthIT/Mobile Health

3:15 – 3:45 pm

Networking and Refreshment Break

3:45 – 4:30 pm

Investing in Agri-Health: Opportunities in the Midwest

4:30 – 5:15 pm

New Models of Financing in Biopharmaceutical Product Development

5:15 – 5:25 pm

Closing Remarks

5:25 – 7:00 pm

Minnesota Warm-up Reception (Joint reception with LSA 2012 Conference)

7:00 pm

Conference Adjourns

Economic Value Analysis: Innovation and How We Pay For It

Printed: November 30, 12

ATTENDEE LISTING

BY COMPANY NAME

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

Abbott Biotech Ventures, Inc. Steven Kuemmerle Head, Venture Investments Lake Forest, IL

Abiogenix

Abiogenix

AdvaMed Ray Briscuso Managing Partner Alexandria, VA

AdvaMed

Advanced Circulatory Systems

Affinity Capital Management Greg Glarner Venture Partner Minneapolis, MN

Affinity Capital Management

Alandra Medical

Allen Executive Search, Ltd. Rich Allen Managing Partner Oconomowoc, WI

Altheus Therapeutics, Inc.

Alung Technologies, Inc.

American Medical Systems Max Fiore Chief Technology Officer Minnetonka, MN

American Medical Systems

Arboretum Ventures

Arboretum Ventures Timothy Petersen Managing Director Ann Arbor, MI

Armentum Partners

Armentum Partners

Arthur Ventures James Burgum Managing Partner Fargo, ND

Arthur Ventures

Ascenix Biotech

Asthmapolis Mark Gehring President & Co-­‐founder Madison, WI

Asthmapolis

Ativa Medical

Ativa Medical Corporation David Deetz President & CEO St. Paul, MN

Atterocor, Inc.

Baird Venture Partners

Baxter Healthcare Midori Yokoyama Managing Director, Baxter Ventures Deerfield, IL

BBC Entrepreneurial Training & Consulting

BBC Entrepreneurial Training & Consulting

Sara Cinnamon Co-­‐Founder Cambridge, MA Andrew Calhoun Executive Vice President Alexandria, VA

Kris Johnson President Minneapolis, MN

Dennis Schafer CEO Oklahoma City, OK

David Yonce Director, New Product Incubation Minnetonka, MN Chris Carthy Managing Partner San Jose, CA Patrick Meenan Director Fargo, ND

David Van Sickle CEO Madison, WI Julia Owens President & CEO Ann Arbor, MI

Becky Aistrup Ann Arbor, MI

Goutam Reddy Co-­‐Founder Cambridge, MA Mike Black CEO Roseville, MN

David Hite CEO E. Palo Alto, CA

Pete DeComo Chairman & CEO Pittsburgh, PA Kristin Myers Principal Ann Arbor, MI

Brian Demmert Managing Partner San Jose, CA William Faulkner CEO Saint Paul, MN Dennis McFadden CFO St. Paul, MN Peter Shagory Partner Chicago, IL

Lisa Kurek Managing Partner Ann Arbor, MI

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

BCC, Inc. Marshall Ring CEO Winnipeg, MB

Bethel University

BioEnterprise, Inc.

BioGenerator Eric Gulve President St. Louis, MO

BioGenerator

BioGenerator/BioSTL

BioMotiv Baiju Shah CEO Cleveland, OH

Biopeople

BioScopeX ApS

BioScopeX ApS Ole Kjeldsen CEO Struer, Denmark

BlueCross BlueShield Venture Partners

Boston Scientific

Brimacomb & Associates Rick Brimacomb Founder Minneapolis, MN

BSI

Burrill & Company

Cairn Ventures Lisa Crump CEO Wayzata, MN

Capital Advisors Group

Capital Midwest Fund, L.P.

Capital Royalty Fund Luke Duster Principal Houston, TX

Capital Royalty Fund

CardioInsight Technologies, Inc.

CardioInsight Technologies, Inc. Patrick Wethington President & CEO Cleveland, OH

Cell Habitats

CG3

Chartwell Capital Solutions Wil Becker Managing Director Minneapolis, MN

Chartwell Capital Solutions

Chitogen, Inc.

Chitogen, Inc. Michael Reilly CEO Minneapolis, MN

CID / Fletcher Spaght

CincyTech

Jim Fitzgerald St. Paul, MN

Edward Hamati Principal Saint Louis, MO

Sophie Labrosse Science Liaison Officer Copenhagen, Denmark Michael Spadafore Analyst Chicago, IL Todd Moorman Assistant VP Reston, VA Stefan Spazek Senior Vice President Newton, MA Nathan Hukill Managing Director Houston, TX John Flavin CEO Woodridge, IL Carrie Willis Associate Minneapolis, MN

Peter Kleinhenz Managing Director/CID Venture Partner/Fletcher Spaght Columbus, OH

Karen Spilizewski Vice President Cleveland, OH Dan Broderick Vice President St. Louis, MO

Henrik Harboe Consultant Holte, Denmark Dean Briesemeister Director New Business Development St. Paul, MN Greg Young Managing Director San Francisco, CA Dan Einhorn General Partner Milwaukee, WI

Kevin Mendelsohn VP Finance & Corporate Development Cleveland, OH Patrick Kullmann CEO Minneapolis, MN Douglas Eayrs CFO Minneapolis, MN

Emily Easley Investment Analyst Cincinnati, OH

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

CincyTech Jan Rosenbaum Director, Life Sciences Cincinnati, OH

CitareTx Investment Partners

Coloplast

Coloplast Corp.

Jon Wood Director of Strategic Development Minneapolis, MN

Comprehensive Reimbursement Solutions

Critical Perfusion, Inc.

Dalmore Investments Jeffrey Blank Associate Minnetonka, MN

Dalmore Investments

Delphinus Medical Technologies, Inc.

Delphinus Medical Technologies, Inc. William Greenway CEO Plymouth, MI

Devicix, LLC

Diagnostic Photonics, Inc.

Dohmen Tamie Joeckel Vice President Business Development Milwaukee, WI

Dorsey & Whitney LLP

Dorsey & Whitney LLP

Dorsey & Whitney LLP Rhona Schmidt Partner Minneapolis, MN

Dymedex Consulting

Early Stage Partners

Elsevier Business Intelligence David Cassak VP, Content & Managing Director, Medical Devices

Empathic Clinical Suite, LLC

Envoy Medical

Essex Woodlands Health Ventures Guido Neels Managing Director Palo Alto, CA

EvaluatePharma USA, Inc.

EvaluatePharma USA, Inc.

EvaluatePharma USA, Inc. Debbie Paul CEO Americas Boston, MA

Faegre Baker Daniels LLP

First Analysis

First Green Partners Doug Cameron Co-­‐President & Director Minneapolis, MN

Flagship Ventures

Flow Forward Medical, LLC

Jeffery Sheldon General Partner & Mangaging Director Houston, TX Bob Thompson President Circle Pines, MN

John Blank President Minnetonka, MN Peter DeLange CEO Eden Prairie, MN

Robert Kuhns Partner Minneapolis, MN

Joseph Galatowitsch President & Managing Partner Shoreview, MN Debra Lindell CEO Wayzata, MN

Christine Lindgren Head of Marketing Boston, MA Jason Kraus Partner Minneapolis, MN

Michael Johnson Associate Cambridge, MA

Mike Witzmann Concept Development Manager Minnneapolis, MN Kevin Davidson CEO Lakeville, MN

John Dahler CFO Plymouth, MI

Andrew Cittadine President & CEO Chicago, IL Jeffrey Saunders Partner Minneapolis, MN

Michael Bunker Managing Director Cleveland, OH Bill Murray CEO Saint Paul, MN

Brian O-­‐Neil Manager, Sales & Solutions, MedTech Boston, MA Tracy Marshbanks Managing Director Chicago, IL

Nicholas Franano CEO & President Olathe, KS

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

FluGen, Inc. Paul Radspinner President & CEO Madison, WI

Fredrikson & Byron, PA

Freemind Consultants

Frost & Sullivan Charlie Whelan Director of Consulting Healthcare & Lifesciences, North America San Antonio, TX

Furst Group

GE Capital, Healthcare Financial Services

GE Capital, Healthcare Financial Services Joseph Hammer Vice President, Sales Chicago, IL

GE Capital, Healthcare Financial Services

GE Healthymagination Fund

General Blood, LLC David Mitchell Co-­‐Founder Minneapolis, MN

General Mills, Inc.

Governor's Office of Economic

Gray Plant Mooty Kermit Nash Attorney Minneapolis, MN

H.I.G. BioVentures

Healthsense, Inc.

Heron Capital Kevin Etzkorn Managing Director Carmel, IN

HilkerWorks

Hill-­‐Rom

HistoSonics, Inc. Thomas Davison Chairman & CEO Ann Arbor, MI

HistoSonics, Inc.

Hopen Life Science Ventures

Hopen Life Science Ventures Nathan Fredrickson Associate Grand Rapids, MI

Hopen Life Science Ventures

Hopen Life Science Ventures

iBIO Institute Barbara Goodman SVP, Propel Chicago, IL

IllinoisVENTURES, LLC

ImmuneWorks, Inc.

Imricor Medical Systems, Inc. Gregg Stenzel VP Operations Burnsville, MN

Imricor Medical Systems, Inc.

Imricor Medical Systems, Inc.

James Snelson Attorney Minneapolis, MN Tim Frischmon Principal Minneapolis, MN

Benjamin Wunderlich ECLP Norwalk, CT

Dave Wagner VP, External Partner Development Minneapolis, MN

Michael Wasserman Managing Director Miami, FL Georgie Hilker Founder

Christine Gibbons President & COO Ann Arbor, MI Mike Fulton Managing Director Grand Rapids, MI

John Banta CEO & Managing Director Chicago, IL

Dan Sunnarborg VP R&D Burnsville, MN

Ayal Ronen Vice President Boston, MA

Neil Bonanno Sr. Vice President, National Sales Norwalk, CT

Noah Lewis Managing Director Chicago, IL

Development Melvin Ustad Director of Commercialization Sioux Falls, SD Brian Bischoff CEO

Kari Roehrich Director of Reimbursement Services St. Paul, MN Gerald Callahan Managing Director Grand Rapids, MI Mark Olesnavage Managing Director Grand Rapids, MI Wade Lange President & CEO Indianapolis, IN

Steve Wedan President & CEO Burnsville, MN

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

Innovative Pulmonary Solutions Steve Mertens Sr. VP of Research & Developoment

Inspiration Medical Technology, Inc.

Integrated Project Management Company

Integrated Project Management Company Dorene Lynch Business Development Executive Burr Ridge, IL

IntelliCyt Corporation

International Business Forum

International Business Forum Craig Simak Chief Strategy Officer Jericho, NY

Intuitive Biosciences, Inc.

Invibio Biomaterials Solutions

JumpStart, Inc. Lynn-­‐Ann Gries Investment Officer Cleveland, OH

Kansas Bioscience Authority

KPMG

KPMG Andrew Lanik Partner Minneapolis, MN

KPMG

KPMG

KPMG Chris Schroeder Managing Director Minneapolis, MN

KPMG

Laureate Biopharma Servcies Inc.

Lemhi Ventures Jodi Hubler Managing Director Excelsior, MN

LifeScience Alley

LifeScience Alley

LifeScience Alley Bekah Kent VP Medical Technology Cluster St. Louis Park, MN

LifeScience Alley

LifeScience Alley

LifeScience Alley & BioBusiness Alliance of Minnesota Dale Wahlstrom President & CEO St. Louis Park, MN

Lindquist & Vennum

Linear, LLC

Linear, LLC Jeff Sweeney Marketing Manager Business Development Carlsbad, CA

Linn Grove Ventures

Lucid Capital

Stephen Miller Co-­‐Founder Eagan, MN

Terry Dunlay CEO Albuquerque, NM

Shawn Guse President & CEO Madison, WI

David Vranicar President Heartland BioVentures Olathe, KS Brian Mensink Partner Minneapolis, MN Kevin Smith Partner Minneapolis, MN Dana Boyle VP, Community Engagement Minneapolis, MN Shaye Mandle COO St. Louis Park, MN Barbara Rummel Partner Minneapolis, MN

John Deedrick Managing Director Rochester, MN

Diana Twyman Business Development Executive Burr Ridge, IL Danielle Pappas Executive Producer Jericho, NY

Nicole Czechowski Business Development Manager West Conshohocken, PA Eric Berglund Audit-­‐Senior Manager Minneapolis, MN Paul Patefield Audit-­‐Senior Manager Minneapolis, MN Alex Ye Senior BD Manager Highland Park, NJ

Chris Hanson Business Development St. Louis Park, MN Joe Shaw VP of Innovation St. Louis Park, MN Chuck Stevens VP Health Business Unit Carlsbad, CA

Tim Hillukka Managing General Partner Minnetonka, MN

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

Mayo Clinic Ventures Ron Amodeo Director, Business Development Rochester, MN

Mayo Clinic Ventures

Mayo Clinic Ventures

Mayo Clinic Ventures Nathan Stacy Instrument & New Ventures Director Rochester, MN

Med Qiao Group, LLC

Medafor, Inc.

MedCelerate Greg Davis CEO Chapel Hill, NC

MedCity News

MedCity News

MedCity News Amanda Todorovich Chief Content Officer Cleveland, OH

Medical Device Innovation Consortium

Medical Device Innovations, Inc.

Medical Device Manufacturers Association Mark Leahey President & CEO Washington, DC

MediTech Strategic Consultants, B.V.

MediTech Strategic Consultants, B.V.

MedLinX Medtech Karin Roof Principal Saint Paul, MN

Medtronic, Inc.

Medtronic, Inc.

Medtronic, Inc. Chris King VP Business Development & Strategic Partnering Mounds View, MN

Medtronic, Inc.

Medtronic, Inc.

Medtronic, Inc. Jitesh Tank Director, Business Development Minneapolis, MN

Medtronic, Inc.

Merck

Metactive Medical, LLC Xandra Sifuentes President Olathe, KS

Michigan Accelerator Fund

Minnesota Angel Network

Minnetronix, Inc. Jeremy Maniak VP of New Ventures & Engineering St. Paul, MN

Monteris Medical Corp.

NAMSA

Andrew Danielsen Business Development Manager Rochester, MN Jean Yao Managing Partner Blaine, MN

Arundhati Parmar Reporter Minneapolis, MN Maura Donovan Executive Director Minneapolis, MN

Frank Keulen Project Manager / CRA Vaals, Netherlands Anil Asrani Investor Relations Minneapolis, MN

Joseph Knight Business Development Associate Mounds View, MN

Meredith Wank Senior Product Manager, Global Upstream Brady Mounds View, MN Dale Grogan Managing Director Grand Rapids, MI

John Schellhorn President & CEO Plymouth, MN

Jeremy Friese Interventional Radiologist Rochester, MN Gary Shope CEO Minneapolis, MN

Chris Seper CEO Cleveland, OH

Michael Dale President & CEO Plymouth, MN

Roy Lohmann Business Manager Vaals, Netherlands

Julie Brewer Vice President/CVG Strategic Sales Minneapolis, MN Mark Pacyna Sr. Director, Corporate Development Minneapolis, MN

Susan Rohrer Executive Director, Licensing & External Research Rahway, NJ Todd Leonard Executive Director St. Louis Park, MN

Tim Blair Director, Business Development Minneapolis, MN

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

NAMSA Chris Pulling Vice President Minneapolis, MN

NAMSA

National Venture Capital Association

Nerve Access, Inc. Yaser Maksoud President & CEO Chicago Ridge, IL

North Texas RCIC

NxThera, Inc.

NxThera, Inc. J. Robert Paulson President & CEO Maple Grove, MN

Oak Ridge Financial

Ocumed

Oppenheimer Wolff & Donnelly LLP Patrice Kloss Attorney Minneapolis, MN

Oppenheimer Wolff & Donnelly LLP

OrthoCor Medical

Perkins Coie LLP Bruce Zivian Partner Chicago, IL

PharmaCline

Pharmatek Laboratories, Inc.

PhRMA Linda Carroll-­‐Shern North Central Regional Director St. Paul, MN

Piper Jaffray & Co.

Piper Jaffray & Co.

Preceptis Medical, Inc. Steve Anderson CEO Plymouth, MN

Preventice

Project Leadership Services

Prolog Ventures Brian Clevinger Founder & Managing Director St. Louis, MO

Pulse Therapeutics, Inc.

QuickCheck Health, Inc.

Respicardia, Inc. Tim Hauch CFO Minneapolis, MN

Respira Therapeutics, Inc.

ReUrban, LLC

River Cities Capital Funds David Kereiakes Senior Analyst Cincinnati, OH

Rose Ventures, Inc.

SciMar Ltd

Ann Quinlan Smith Division President, Clinical & Consulting Minneapolis, MN Maria Smith-­‐Brackenridge Director Dallas, TX

Randy Hines Senior Managing Director Golden Valley, MN Thomas Letscher Chair Minneapolis, MN Steven Keough CEO Sioux Falls, SD Tom Halverson Managing Director & Group Head, Clean Technology & Industrials Minneapolis, MN Mike Smith CTO Rochester, MN Jim Wachtman CEO St. Louis, MO

Bob Curtis President & CEO Austin, TX

Stan Rose President Madison, WI

Mark Heesen President Arlington, VA

Carmen Bringgold CFO & Sr. VP Commercialization Maple Grove, MN

Les Bogdanowicz Founder Park Ridge, IL John Dinusson President & CEO Minneapolis, MN

Rob Rigney Business Development Director San Diego, CA J.P. Peltier Managing Director Minneapolis, MN

Toni Nosbush Prin. Partner Maple Grove, MN Tom Henke President & CEO Excelsior, MN

Dixon Diebold Angel Investor Minneapolis, MN

Mick Lautt CEO Dauphin, MB

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

Securus Medical Group Inc. Donna Richardson President & CEO Cleveland, OH

Shamrock Structures, LLC

Sikich Investment Banking

Sikich Investment Banking Susan Tomilo Director Chicago, IL

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank Nicholas Honigman Relationship Manager St Louis Park, MN

Silicon Valley Bank

Siloam Biosciences, Inc.

Siloam Biosciences, Inc. Aniruddha Puntambekar COO Cincinnati, OH

SironRx Therapeutics, Inc.

Sister Kenny Research Center

Sorin CRM USA, Inc. Dan Hackman Sr. VP US CRDM Plymouth, MN

Sphaera Technologies Inc.

Square 1 Bank

Square 1 Bank Scott Foote Founder, SVP Managing Director Life Sciences San Diego, CA

STATKING Clinical Services

Stenoien, LLC

Strawn Arnold Jeff Dodson Executive Vice President Hinsdale, IL

Summit Medical, Inc.

Sword Diagnostics, Inc.

Sword Diagnostics, Inc. Rob Donoho Chief Operating Officer Chicago, IL

Teijin Pharma Ltd

Teijin Pharma Ltd

TGap Ventures, LLC Jack Ahrens General Partner Kalamazoo, MI

The Network Connect

The Whistle

Thomas, McNerney & Partners Pete McNerney Partner Minneapolis, MN

Thomas, McNerney & Partners

Torax Medical

Michael Flavin CEO Woodridge, IL

Brittany Clements St. Louis Park, MN

Jay McNeil Managing Director St. Louis Park, MN Evan Facher President & CEO Cleveland, OH

John Pacak President and CEO Winnipeg, MB

Jeff Osterhaus Senior Contracts Manager Fairfield, OH

Kevin McIntosh Executive VP, COO St. Paul, MN Tsuneo Deguchi Manager Novato, CA

Dick Sommerstad Relationship Catalyst Apple Valley, MN

Kathy Tune Partner Minneapolis, MN

Adam Elhofy Vice President Chicago, IL

John Hoesley Managing Director Chicago, IL

Chong Ahn President & CEO Cincinnati, OH

Lars Oddsson Director of Research Minneapolis, MN

Barbara Fleming SVP, Venture Capital Services East Manager Durham, NC Mark Stenoien Principal Plymouth, MN

David Dingott President & CEO Chicago, IL

Naohiko Moriyama General Manager, Business Strategy Department Chiyoda-­‐ku, Tokyo John West Founder & Chairman New York, NY

Brian Mower VP of Finance Shoreview, MN

10TH ANNUAL MIDAMERICA HEALTHCARE VENTURE FORUM December 4, 2012 | Hyatt Regency Minneapolis, MN Attendee List Sorted by Company Name

Triathlon Medical Ventures/ AllTranz, Inc. George Emont Managing Partner/ Chairman and Acting President Louisville, KY

Triathlon Medical Ventures

TriNet

TripleTree Chris Hoffmann Senior Director & Chief Marketing Officer Minneapolis, MN

Tysvar, LLC

Tysvar, LLC

Ubiqi Health, Inc. Anshuman Sharma Chief Technology Officer Somerville, MA

UnitedHealth Group

UnitedHealth Group

University of Minnesota Connie Delaney Dean, School of Nursing Minneapolis, MN

University of Minnesota

University of Minnesota

University of Minnesota Justin Porter Associate St. Paul, MN

University of Minnesota

University of Minnesota

University of Minnesota, Office for Technology Commercialization Russ Straate Venture Center Associate Director St. Paul, MN

University of Saskatchewan

University of Wisconsin-­‐Madison-­‐OCR

Venture Investors, LLC George Arida Managing Director Madison, WI

Venture Investors, LLC

Venture Investors, LLC

Vital Simulations, LLC Don Gerhardt Chairman

Wild GmbH

Wild GmbH

Wilkerson Guthmann Ron Lenz Principal Saint Paul, MN

Wright Medical Technology, Inc.

Zipnosis

Chas McKhann Edina, MN

John Rice Managing Partner Cincinnati, OH

Ellen Ewald Partner Minneapolis, MN

Jayant Parthasarathy Director-­‐Innovation and R&D Minnetonka, MN Douglas Johnson Director St. Paul, MN

Jay Schrankler Executive Director St. Paul, MN

Neal Lemon Technology Transfer Officer Saskatoon, SK

Loren Peterson Managing Director Madison, WI

Harald Londer Manager Business Development Voelkermarkt, Austria John Warmath Director, Market & Business Development Arlington, TN

Tom Nelson Life Sciences Sales Consultant Cary, NC

David Richter Principal Minneapolis, MN

Robert Plourde VP-­‐Innovation and R&D Minnetonka, MN Eric Kaler President Minneapolis, MN

James Teter Venture Center, Office for Technology Commercialization Minneapolis, MN Allen Dines Asst Director Corporate Relations Madison, WI

Paul Weiss Managing Director Madison, WI

Adrian Pinter DI Voelkermarkt, Austria Jonathan Pearce CEO St. Paul, MN